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aa  Amino Acid
AC   Adenylyl cyclase
Act  Activin
ActRII  Activin type II receptor
Ad-  Adenovirus-
ALK  Activin receptor-like kinase
AMH  Anti-Müllerian hormone
AMHRII Anti-Müllerian hormone type II receptor
AMP  Adenosine monophosphate
ATP  Adenosine triphosphate
BAMBI  BMP and activin membrane-bound inhibitor
BMP  Bone morphogenetic protein 
BMPRII  Bone morphogenetic protein type II receptor
BRE   BMP responsive element
ca  Constitutively active
cAMP  Cyclic adenosine monophosphate
C-terminal Carboxy-terminal
CEEF  Cumulus expansion enabling factor
Co-Smad Common-partner Smad
COX2  Cyclo-oxygenase 2 (Ptgs2)
ER  Endoplasmic reticulum
EGF  Epidermal growth factor
EP2  Prostaglandin E2 receptor
Erk  Extracellular signal-regulated kinase
FS  Follistatin
FSH  Follicle stimulating hormone
FSHR  Follicle stimulating hormone receptor
GCNF  Germ cell nuclear factor
GDF  Growth diff erentiation factor 
HAS  Hyaluronan synthase
hGL  Human granulosa-luteal cell
hCG   Human chorionic gonadotropin
I-Smad  Inhibitory Smad
IGF  Insulin-like growth factor
Inh   Inhibin
kd  Kinase defective 
KL  Kit ligand
LAP  Latency associated protein
LH  Luteinizing hormone
LHR  Luteinizing hormone receptor
LTBP  Latent TGF-  binding protein
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MAPK   Mitogen activated protein kinase
MH  Mad homology domain
MIS  Müllerian inhibiting substance
m.o.i.  Multiplicity of infection
mRNA   Messenger ribonucleic acid 
N-terminal Amino-terminal
NES  Nuclear export signal
NLS  Nuclear localization signal
OD   Ovarian dysgenesis
OSF  Oocyte secreted factor
PCOS  Poly cystic ovary syndrom
PGC  Primordial germ cell
PGE2  Prostaglandin E2
PKA/B/C  Protein kinase A, B or C
POF  Premature ovarian failure
Ptgs2   Prostaglandin endoperoxide synthase 2 (COX2)
PTX3  Pentraxin 3
PY-domain Proline-tyrosine rich domain
R-Smad  Receptor-activated Smad
SBE  Smad binding element
SAD   Smad activation domain
SARA  Smad anchor for receptor activation
Ser  Serine
siRNA  Small interfering RNA
Smufr   Smad ubiquitination-related factor
StAR  Steroidogenic acute regulatory protein
STAT   Signal transducer and activator of transcription
TGF-   Transforming growth factor 
T RII  Transforming growth factor  type II receptor
Th r   Th reonine
TNFIP6  Tumor necrosis factor-induced protein 6
uPA  Urokinase plasminogen activator
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Since the discovery of the transforming growth factor  (TGF- ) over twenty years 
ago, more than thirty structurally related proteins have been identifi ed in vertebrates. Th is 
family now comprises of activins, inhibins, growth diff erentiation factors (GDFs), bone 
morphogenetic proteins (BMPs) and many others. Th e biological eff ects of the TGF  
family ligands are mediated to the target cells via heteromeric complexes of type I and II 
serine/threonine kinase receptors which activate the intracellular Smad signalling protein 
pathways in various cell types. 
In the ovary, two new members of the superfamily were discovered during the 1990s. 
Th e oocyte was discovered to express two closely related growth factors that were named 
growth diff erentiation factor 9 (GDF-9) and growth diff erentiation factor 9B (GDF-9B, 
also known as BMP-15). Th ese proteins are both required for normal ovarian follicle 
development although their individual signifi cance has been shown to vary between 
diff erent species. Both GDF-9 and GDF-9B mRNAs are expressed in the human oocytes 
from the primary follicle stage onwards.
Th is thesis project was aimed to defi ne the signalling mechanisms utilized by the oocyte 
secreted GDF-9. We used primary cultures of human granulosa luteal cells (hGL) as our 
cell model, and recombinant adenovirus-mediated gene transfer in manipulating the TGF-
 family signalling cascade molecules in these cells. Overexpression of the constitutively 
active forms of the seven type I receptors, the activin receptor-like kinases 1-7 (ALK1-7), 
using recombinant adenoviruses caused a specifi c activation of either the Smad1 or Smad2 
pathway proteins depending on the ALK used. Activation of both Smad1 and Smad2 
proteins stimulated the expression of dimeric inhibin B protein in hGL cells.
Treatment with recombinant GDF-9 induced the specifi c activation of the Smad2 
pathway and stimulated the expression of inhibin B subunit mRNA as well as inhibin 
B protein secretion in our cell model. Recombinant GDF-9 was also able to activate 
the Smad3-responsive CAGA-luciferase reported construct and the GDF-9 response in 
hGL cells was markedly potentiated upon the overexpression of Alk5 by adenoviral gene 
transduction. Alk5 overexpression also enhanced the GDF-9 induced inhibin B secretion 
by these cells. Similarly, in a mouse teratocarcinoma cell line P19, GDF-9 could activate the 
Smad2/3 pathway, and overexpression of ALK5 in COS7 cells rendered them responsive 
to GDF-9. Furthermore, transfection of rat granulosa cells with small interfering RNA for 
ALK5 or overexpression of the inhibitory Smad7 resulted in dose-dependent suppression 
of GDF-9 eff ects. 
In conclusion, this thesis shows that both Smad1 and Smad2 pathways are involved 
in controlling the regulation of inhibin B secretion. Th erefore, in addition to endocrine 
control of inhibin production by the pituitary gonadotropins, also local paracrine factors 
within in the ovary, like the oocyte-derived growth factors, may contribute to controlling 
inhibin secretion. Th is thesis shows as well that similarly to other TGF-  family ligands, 
ABSTRACT
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also GDF-9 signalling is mediated by the canonical type I and type II receptors with 
serine/ threonine kinase activity, and the intracellular transcription factors, the Smads. 
Although GDF-9 binds to the BMP type II receptor, its downstream actions are specifi cally 
mediated by the type I receptor, ALK5, and the Smad2 and Smad3 proteins. 
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Th e most important functions of the ovary are the production of steroid hormones 
that allow sexual maturation and the production of oocytes capable of fertilization. Several 
growth factors that belong to the transforming growth factor  (TGF- ) superfamily as well 
as their receptors and intracellular eff ector molecules, have been shown to be indispensable 
for the critical ovarian functions such as oocyte formation and development as well as 
ovarian folliculogenesis [1-3]. Th e expression of these signalling cascade molecules is 
tightly regulated at the diff erent phases of ovarian organogenesis as well as folliculogenesis. 
Th eir specifi c expression patterns determine the responsiveness of the ovarian cell types 
to each stimulus in the right place and at the right time. Accordingly, fl aws along the 
signalling cascade at either the ligand, receptor or intracellular eff ector level may cause 
adverse changes in the intended message leading to fertility defects of varying severity, as 
has been demonstrated by extensive knockout studies in mice [3]. 
Th e TGF-  superfamily comprises of e.g. the three isoforms of TGF- , the activins and 
inhibins, growth diff erentiation factors (GDFs) and bone morphogenetic proteins (BMPs) 
which all share common sequence elements as well as structural motifs. Th e superfamily 
ligands regulate a wide variety of cell functions including proliferation, diff erentiation, 
migration as well as apoptosis. Th ey also stimulate the production of extracellular matrix, 
maintain tissue homeostasis and regulate embryogenesis. Th e TGF-  superfamily ligands 
are bioactive as homo- or heterodimers and they signal through a distinct set of type I and 
II serine/threonine kinase receptors that are located on the plasma membrane. Th e ligand 
dimer together with the transmembrane receptors forms a large signalling complex that is 
capable of activating the intracellular eff ector molecules, the Smads.
Five type II Ser/Th r kinase receptors, and seven type I receptors have been identifi ed 
so far. Th e type II receptor is thought to be constitutively active and it activates the type I 
receptor by phosphorylating specifi c serine residues at its glycine-serine rich GS-domain. -
glycan and endoglin function as accessory receptors (“type III receptors”) and may modulate 
the bioactivity of some of the superfamily ligands. When a ligand-receptor complex has 
formed, diff erent receptor-regulated (R)-Smads are activated through phosphorylation by 
the type I receptor. Altogether eight diff erent Smads have been found in mammals and 
they are commonly classifi ed into three groups according to their function. Receptor-
regulated Smads (Smad1, -2, -3, -5 and -8) are activated upon ligand binding to the 
receptor complex, common partner (Co)-Smad (Smad4) translocates into the nucleus 
with the activated R-Smads and is also required for transcription. Smad2 and Smad3 can 
be phosphorylated by the activated TGF- /activin type I receptors, whereas Smad1, -5 and 
-8 act downstream of the type I BMP receptors. Th e translocated Smad complexes regulate 
target gene expression in interaction with other transcription factors, co-activators and co-
repressors. Th e function of the inhibitory (I)-Smads is to block the activation of R-Smads 
at the type I receptor (Smad7) or their translocation into the nucleus (Smad6). Inhibitory 
Smads can block TGF-  superfamily signalling by binding to the type I receptors (Smad7) 
INTRODUCTION
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or by competing with activated R-Smad1 for binding to Co-Smad4 (Smad6). Smad7 can 
inhibit the activation of both the TGF- /activin and BMP pathway R-Smads, whereas 
Smad6 is an inhibitor of BMP signalling (reviewed in [4-6]). 
Previously it was thought that the oocyte had a passive role in the events of 
folliculogenesis and the somatic granulosa cells were the main eff ectors. However, it is 
now known that a bi-directional communication axis exists between the oocyte and the 
surrounding somatic cells; the oocyte regulates the diff erentiation and proliferation of 
the granulosa cells which in return secrete factors that control the growth of the oocyte. 
Consequently, a complex interplay of regulatory factors governs the development of both 
cell types. Many endocrine, paracrine and autocrine factors including several TGF-  
superfamily members are expressed by diff erent cell types in the ovary and they contribute 
to the regulation and progression of the folliculogenesis. 
Th e fi rst part of this thesis, the review of the literature section, is focused on the TGF-  
signalling pathway molecules and signalling mechanisms. In the fi rst part, also the course 
of ovarian folliculogenesis is shortly reviewed and the biological roles of the oocyte secreted 
growth diff erentiation factors GDF-9 and GDF-9B are described. Th e second part of this 
thesis is focused on the study of the signalling pathway used by GDF-9.
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REVIEW OF THE LITERATURE
1. TGF-  superfamily of growth factors
Th e fi rst member of the transforming growth factor  (TGF- ) superfamily was 
discovered in the early 1980s as a growth factor that caused phenotypic transformation and 
anchorage-independent growth in non-neoplastic rat fi broblast cells [7]. Today, more than 
thirty structurally related proteins have been identifi ed in vertebrates including the three 
isoforms of TGF- , bone morphogenetic proteins (BMPs), growth diff erentiation factors 
(GDFs), activins, inhibins, anti-Müllerian hormone (AMH) and several others. Th ese 
proteins regulate many of the most important features of living organisms; cell growth, 
diff erentiation, migration, apoptosis, embryonic development, morphogenesis and sexual 
development. Defects along the signalling pathway of the TGF-  superfamily members are 
associated with a variety of pathological states such as cancer and autoimmune diseases [8]. 
1.1. Characteristics of the TGF-  superfamily ligands
Th e diff erent TGF-  superfamily members share certain characteristic structural 
features and exhibit sequence similarity. All superfamily members are synthesized as large 
precursor molecules (pre-pro-proteins) consisting of an amino (N-) terminal signal peptide, 
followed by a pro-region and a carboxy (C-) terminal mature region that is biologically 
active (Figure 1). Th e signal peptide directs the protein to the secretory pathway. First, in 
the lumen of endoplasmic reticulum (ER), the signal sequence is cleaved. Subsequently, the 
proprotein becomes folded and dimerizes within the ER, and fi nally proteolytic cleavage 
in the trans-Golgi network by furin-like endoproteases releases the mature peptide from 
the pro-region. 
Figure 1. TGF-  superfamily ligand structure. NH3, amino-terminus; COOH, carboxy-
terminus; S, signal sequence; black line, intermolecular disulfi de bond; red C, the 
fourth cysteine residue lacking in GDF-9 and GDF-9B.
Mature -region      S Pro-region  NH3- -COOH
C  C  C  C   C   C    C 
Mature i  
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Th e signifi cance of the pro-region is not well known for each ligand but it has been 
suggested to be required for proper folding of the mature region [9]. Th e dimeric pro-
regions of the TGF-  isoforms (known as latency associated proteins, LAPs) remain 
attached to the mature protein via noncovalent associations after cleavage, forming a 
latent, biologically inactive complex. TGF-  and the associated LAP further form larger 
latent complexes with latent TGF-  binding proteins (LTBPs). Th ese complexes anchor 
the latent TGF-  to the extracellular matrix (ECM) due to specifi c interactions of LTBPs 
with the ECM components which represents the predominant way of storage of the 
latent TGF- . Th e latent form of TGF-  can be activated through enzymatic or chemical 
cleavage, although the physiological conditions that promote the activation of TGF-  in 
vivo are not well understood. 
One of the major eff ects of TGF-  is the inhibition of cell proliferation and induction 
of apoptosis in a variety of cell types [10]. It has recently been shown that the proteolytic 
activation of latent TGF-  enhances apoptotic response in lung epithelial cells and 
suppresses both PI-3K/Akt (Phosphoinositide 3 kinase and a serine/threonine kinase 
also known as protein kinase B, respectively) and p38 MAPK (mitogen activated protein 
kinase)-dependent survival pathways [11]. While the mature regions of TGF-  dimer 
form the bioactive molecule, another superfamily member, AMH, instead requires the N-
terminal pro-region for optimal bioactivity [12]. Th e signifi cance of the pro-region for the 
bioactivity of other superfamily members remains to be further studied. 
Another characteristic feature of this protein family is that they contain from six to 
nine evolutionarily conserved cysteine residues in their C-terminal mature region. Six of 
these cysteines form three covalent disulfi de bonds within the molecule resulting in a tight 
structure called the cysteine knot [13]. Th e seventh conserved cysteine residue (fourth 
consecutive cysteine from the N-terminus) present in most TGF-  superfamily members 
is involved in forming the covalent intermolecular disulfi de bond in the ligand dimer [14, 
15]. However, some superfamily members such as GDF-3, GDF-9, GDF-9B/BMP-15 as 
well as lefty-1 and lefty-2 lack this cysteine residue due to a substitution of an amino acid 
residue, and therefore these growth factors are unable to form covalent dimers (see Figure 
1). Instead,  the ligand monomers may remain associated through noncovalent binding 
[16-20]. 
2. The signalling pathway
2.1. Type I and II receptors
Th e members of the TGF-  superfamily are known to signal through specifi c 
transmembrane serine/threonine kinase receptor complexes consisting of two type I 
and two type II receptor molecules. Currently fi ve type II receptors (ActRII, ActRIIB, 
BMPRII, T RII and AMHRII) and seven type I receptors are known (activin receptor-
like kinase (ALK) 1-7) (see Tables 1 and 2, respectively) [21, 22]. All these receptors are 
structurally related, although their kinase domains are functionally diverged. Th e receptor 
polypeptides consist sequentially of an N-terminal extracellular domain followed by a 
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transmembrane region and a C-terminal intracellular serine/threonine kinase domain. 
Th e type I receptors act downstream of the constitutively active type II receptors and both 
receptor types are required for proper signalling. 
Table 2. The type I receptors of the TGF-  superfamily and the 
ligands known to bind the receptor.
Table 1. The type II receptors of the TGF-  superfamily and the 













Ligands binding to the receptor
Activin A, Inhibin A/B, BMP-2, 
BMP-3, BMP-6/7, BMP-10, 
GDF-5/6/7, GDF-8 (myostatin), 
GDF-9B (BMP-15), GDF-11/BMP-11
Activin A, Inhibin A/B, Nodal, 
BMP-2, BMP-6/7, GDF-5, 
GDF-8 (myostatin), GDF-1, GDF-11 
AMH (MIS)
Inhibin A (with T RIII), BMP-2/4, BMP-6/7,


































TGF-  Type III receptor
Inhibin co-receptor
Ligands
TGF- 1, Activin A
TGF- , Activin A, AMH 
(MIS), BMP-6/7
BMP-2/4, BMP-6/7, BMP-10, 
GDF-5/6/7, AMH
Activin A, GDF-1 and Nodal 
(with Cripto), BMP-3, GDF-8, 
GDF-11/BMP-11
TGF- , GDF-8, GDF-9
BMP-2/4, BMP-6/7, BMP-10, 
GDF-5/6/7, GDF-9B (BMP-15), AMH
Nodal
TGF- 1-3, Inhibin A (with ActRIIA)
TGF- 1,3, Activin A, BMP-2/7
Nodal
Inhibin A/B (with ALK4)
References
[44, 45]
[23, 24, 33, 
40, 45-47]
[23, 24, 33, 35, 
38, 48, 49]











Th e TGF-  superfamily ligands bind diff erently to their receptors. TGF-  and 
activin have high affi  nity to the type II receptor and do not interact with the isolated 
type I receptor (Massague 1998 [61] and references therein). In contrast, some BMP 
ligands bind fi rst to type I receptors after which the the type II receptor is recruited to 
the preassembled receptor-ligand complex [61]. An active ternary complex consisting of a 
bound ligand dimer and two type I and two type II receptors causes the type II receptor 
to phosphorylate specifi c serine residues in the glycine-serine rich region (GS-domain) 
located upstream of the kinase domain of the type I receptor. Th e activated type I receptor 
then further activates the downstream eff ector molecules of the superfamily, the Smads 
(see Figure 2 below). 
2.2. Accessory receptors
In addition to these twelve classic receptors, other cell surface proteins, such as -
glycan, endoglin and cripto, have also been shown to interact with the TGF-  superfamily 
ligands and to assist receptor binding. -glycan was the fi rst such molecule reported and 
was designated as a type III TGF-  receptor [62], although it is now known to function 
as a co-receptor for inhibin as well [53]. -glycan is a highly glycosylated transmembrane 
protein with a large extracellular domain and a short cytoplasmic tail that lacks kinase 
activity. It facilitates TGF-  interaction with the type II receptor and promotes inhibin 
binding to activin type II receptor, antagonizing activin signalling. Endoglin is a 
homodimeric integral glycoprotein that is expressed widely in vascular endothelial cells. 
Endoglin cannot bind ligands on its own but facilitates TGF- 1 and -3 binding to their 
receptors through association with the TGF-  type II receptor [63]. Activin and BMP-
7 binding is also facilitated by endoglin through interaction with ActRII and ActRIIB, 
respectively, and in addition, endoglin can bind BMP-2 via the associated type I receptors 
[56]. 
Cripto is a member of the EGF-CFC family of GPI-linked (GPI, a 
glycosylphosphatidylinositol moiety) membrane anchored proteins and is required for 
nodal signalling [26, 58]. Cripto interacts directly with ALK4 and nodal, and is required 
for both the assembly of active ALK4/ActRIIB receptor signalling complexes and Smad2 
activation [26]. Interestingly, cripto also antagonizes activin signalling by forming a 
complex with ActRII and ActRIIB receptors and therefore inhibiting type I receptor 
recruitment. 
A pseudoreceptor called BMP and activin membrane-bound inhibitor (BAMBI) was 
discovered in Xenopus [64] in the late 90s, and based on structural similarities it was later 
recognized as the same protein as the nma (non-metastatic gene A) gene product identifi ed 
in a human melanoma cell line [65]. BAMBI is a transmembrane glycoprotein related to 
the TGF-  superfamily type I receptors, and functions as a negative regulator of TGF-  
signalling during Xenopus embryonic development [64]. BAMBI lacks the intracellular 
kinase domain that is required for signalling and it inhibits TGF-  superfamily ligand 
signalling by forming stable associations with both type I and II receptors in a ligand 
independent manner [64].
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2.3. The Smad protein family
Smad proteins were fi rst identifi ed in the fruit fl y Drosophila melanogaster in the 
mid 90s by Sekelsky et al. who found that an intracellular protein named Mad mediates 
the signalling of decapentaplegic, a member of the TGF-  superfamily corresponding 
to mammalian BMP-2/4 [66]. Th e discovery of orthologous proteins in Caenorhabditis 
elegans (Sma-proteins) as well as in vertebrates soon followed, and the newly found protein 
family was termed Smad [67]. Today, eight diff erent members of the Smad family have 
been identifi ed in mammals. Based on their function, the Smads are classifi ed to receptor-
regulated (R-) Smads (Smad1, -2, -3, -5 and -8), common-partner (Co-) Smads (Smad4 
as well as Xenopus laevis Smad4  and Smad4 ) and inhibitory (I-) Smads (Smad6 and -7). 
Smads mediate the TGF-  superfamily ligand signalling within the cell functioning as 
transcription factors that regulate target gene expression.
Depending on the combination of type I and type II receptors and the presence or 
absence of accessory type III receptors, ligand binding to the receptor complex results in 
the phosphorylation, and therefore the activation, of the diff erent R-Smads. R-Smad2 and 
-3 are phosphorylated by activated TGF- /activin/nodal type I receptors (ALK4,-5 and 
-7), and Smad1, -5 and -8 act downstream of BMP type I receptors (activated by ALK2, 
-3 and -6). ALK1 is a TGF- 1 receptor in endothelial cells that activates the Smad1/5/8 
pathway. Activated R-Smads form oligomeric complexes with Co-Smad4 and translocate 
Figure 2. A schematic drawing of the TGF-  superfamily signalling cascade.
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into the nucleus where they regulate target gene expression in interaction with a multitude 
of other transcription factors, co-activators and co-repressors. Inhibitory Smads block 
TGF-  superfamily signalling by binding to the type I receptors (Smad7) or by competing 
with activated R-Smad1 for binding to Co-Smad4 (Smad6). Smad7 can inhibit the 
activation of both the TGF- /activin and BMP pathway R-Smads, whereas Smad6 is a 
specifi c inhibitor of BMP signalling [4-6]. Th e TGF-  superfamily members signal mainly 
through two distinct Smad-pathways. TGF- , activin and nodal can cause the activation 
of Smad2/3 by the type I receptor, whereas the BMPs activate the Smad1/5/8-pathway 
(see Figure 2).
2.4. The structure of Smad proteins
Smad proteins contain two conserved domains, an N-terminal Mad homology 1 
(MH1) domain and a Mad homology 2 (MH2) domain in their C-terminus, which are 
connected by a non-conserved proline-rich linker region (see Figure 3). Th e MH1 domain 
is highly conserved between the R-Smads and Co-Smads whereas the I-Smads lack a 
recognizable MH1 domain. In contrast, the MH2 domain is highly conserved among all 
Smads. Th e MH1 domain of the R-Smads and Co-Smads binds to DNA with low affi  nity 
recognizing specifi c sequences termed Smad binding elements (SBE) in the promoters of 
their target genes. Smad2, however, lacks DNA-binding ability due to an insertion in the 
exon 3 [68]. Th e MH1 domain confers the ability to interact with other transcription 
factors and contains a nuclear localization sequence (NLS). In addition, the MH1 domain 
physically interacts with the MH2 domain exerting an autoinhibitory eff ect against Smad 
activation [69].
Th e linker region connecting the MH1 and MH2 domains is less conserved between 
the diff erent Smads but contains several important regulatory peptide motifs, including 
potential phosphorylation sites for MAPKs. A proline-tyrosine (PY) motif present in R-
Smads and I-Smads enables Smad interaction with the WW domains of the E3 ubiquitin 
ligases Smurf1 and Smurf2 (Smad ubiquitination-related factors) [70]. In addition, the 
Smad4 linker region includes a nuclear export signal (NES) [71] [72] and a Smad activation 
domain (SAD) that is required in transcriptional complexes mediating the activation of 
Smad-dependent target genes [73].
Th e MH2 domain is a multifunctional region that mediates type I receptor recognition, 
R-Smad oligomerization with Smad4 and transcriptional activation as well as interaction 
with Smad binding proteins and transcription factors. It is also essential for cytoplasmic 
anchoring of the R-Smads. R-Smads are activated through phosphorylation of two serine 
residues at their C-terminal SSXS motif by the activated type I receptor at the inner leafl et 
of the cell membrane. Th e I-Smads and the Co-Smads are not phosphorylated at their C-
terminus. In addition to the C-terminal phosphorylation site, Smads can be phosphorylated 
by other kinases as well. Th e linker region contains phosphorylation sites for extracellular 
signal-regulated kinase (Erk)-family MAP kinases [74], the Ca2+/calmodulin-dependent 
protein kinase II (CamKII) [75] and protein kinase C (PKC) [76].
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Figure 3. A schematic drawing of the Smad structure. Yellow colour marks the 
MH1 domain and blue the MH2 domain. Green triangles show the position 
of the PY-motif in the linker region and the black arrows denote the L3 loop. 
Phosphorylated serine residues at the C-terminus of the R-Smads are marked with 
asterisks. (Modifi ed from Kaivo-oja et al. 2006 [77])
2.5.  Smad-dependent signalling
Inactive R-Smads and Co-Smad4 reside predominantly as monomers in the cytoplasm, 
whereas the I-Smads localize to the cell nucleus. Smad4 constitutively shuttles between 
cytoplasm and nucleus and its cytoplasmic localization in unstimulated cells is due to 
active nuclear export [70, 72]. Cytoskeletal proteins also play a part in the localization and 
signalling of Smads. Unphosphorylated Smad2 and Smad3 bind microtubule fi laments, 
and their dissociation can be induced by TGF-  treatment [78]. Smads may also interact 
with fi lamin, which functions as a scaff old molecule for intracellular signalling proteins 
that crosslinks actin [79]. 
Upon ligand binding, the R-Smads are activated by the activated type I receptor at 
the inner leafl et of the cell membrane through phosphorylation of two serine residues 
at the C-terminus SS*XS* motif (asterisks highlight the phosphorylated serine residues). 
Diff erent ligands can induce distinct signalling pathways depending on the composition of 
the receptor complex. Substrate specifi city between the receptor and Smads is determined 
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L3 loop in the MH2 domain in the R-Smads [80, 81]. Upon ligand binding, the activated 
type I and II receptors are internalized via clathrin coated pits into early endosomes that 
contain a protein named SARA (Smad anchor for receptor activation) [82]. SARA is a 
FYVE domain containing scaff olding protein that interacts with the MH2 domain of 
inactive Smad2 and Smad3 targeting them to early endosomes and aiding the recruitment 
of Smads to their receptors, thus promoting Smad phosphorylation by TGF-  signalling 
[83]. 
A recent report by Runyan et al. shows that endocytosis of the receptor complex is 
required for proper nuclear translocation of activated Smads, and that internalization 
enhances the dissociation of phosphorylated Smad2 from the TGF- -receptor-SARA 
complex [84]. Internalization of the receptor complex through an alternative route, a 
lipid raft/caveolar dependent pathway, leads to the degradation of the receptor complex 
and thus regulates Smad activation and receptor turnover [82]. A cytoplasmic protein 
named PML (promyelocytic leukaemia tumour suppressor) physically interacts with 
Smad2/Smad3 and SARA and is required for the association of Smad2 and -3 with SARA. 
Its expression is induced by TGF-  and it is required for the accumulation of SARA and 
TGF-  receptors in the early endosomes [85]. Several other accessory/scaff olding proteins 
like SARA have been discovered for the TGF- /activin/nodal pathway R-Smads e.g. axin 
and disabled2 (Dab2) [86, 87], but none are yet known for the BMP-pathway Smads. 
Following phosphorylation, Smads can form oligomers at diff erent stoichiometries; 
heterotrimers consisting of two R-Smads and one Smad4 or heterodimers. Activated 
Smads accumulate into the nucleus where they control target gene expression in a cell type 
specifi c manner through interactions with other transcription factors, corepressors and 
coactivators. Diverse ligand responses in diff erent cell types are the result of diff erent Smad-
interacting transcription factors and of cooperation with other signalling pathways.
2.6. Smad-independent signalling and alternative Smad phosphorylation 
In addition to the canonical Smad signalling pathway, other signalling pathway 
molecules have been found to participate in mediating the physiological responses to the 
TGF-  superfamily ligands. For example, TGF-  is known to activate Erk, JNK and p38 
MAPK kinase pathways (reviewed in [88]), although the exact mechanism and biological 
responses are not well characterized. Th ese parallel signalling pathways may co-operate 
with the Smad pathway to elicit specifi c biological responses. Th e non-Smad signalling 
molecules may also directly modify Smad function through alternative phosphorylation, 
and Smads may modulate the activity of other signalling proteins as well. For example, 
TGF- -induced expression of human matrix metalloproteinase 13 (MMP-13) gene in 
gingival fi broblasts is dependent on the activation of two distinct signaling pathways, 
Smad3 and p38 MAPK [89].
Members of the MAP kinase family are frequently involved in TGF- /Smad signalling, 
and Ras activated Erk kinases can modulate the nuclear accumulation of the activated 
Smads. Epidermal growth factor (EGF), hepatocyte growth factor as well as oncogenic 
Ras stimulate Erk kinases, which in turn phosphorylate Smad proteins. Erk kinase 
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phosphorylates specifi c serine residues in the linker regions of Smad1 [74], Smad2 and 
Smad3 [90]. 
Phosphorylation of the Smads may also result from the activation of MAPK/Erk kinase 
kinase 1 (MEKK1), which acts downstream from Ras and upstream from growth factor-
induced Erk MAPK and stress-activated SAPK/JNK pathways [91]. Phosphorylation of 
the Smads in the MAP kinase sites in the linker region attenuates ligand-induced nuclear 
translocation and alters Smad-dependent transcription. Activation of Ca2+/calmodulin-
dependent protein kinase II (CamKII) also results in Smad2, Smad3 and Smad4 
phosphorylation and inhibits TGF- -induced nuclear import and transcriptional activity 
of Smad2, and aff ects Smad heteromerization [75]. Protein kinase C (PKC) abrogates 
the DNA binding ability of Smad3 [76]. Also Smad6 and Smad7 can be phosphorylated 
independently of TGF-  stimulation [92]. 
3. Regulation of  TGF-  superfamily signalling 
TGF-  superfamily signalling is regulated at multiple levels. Ligand access to the 
receptors can be regulated by extracellular antagonists (ligand traps) and specifi c BMP-
binding proteins, or other TGF-  family ligands. At the cell membrane level the signal-
transduction pathway may be broken by the pseudoreceptor BAMBI that can compete 
with the type I receptors for ligand binding and inhibit TGF- , activin and BMP 
signalling [64, 93]. Receptor internalization provides another point for the modulation of 
the signal transduction as discussed above. Intracellular regulation may take place through 
the actions of inhibitory Smads and the regulation of Smad expression levels as discussed 
above.
3.1. Extracellular antagonists and binding proteins 
Several extracellular antagonists that inhibit TGF-  superfamily ligand signalling have 
been identifi ed such as noggin, chordin/SOG (Drosophila short gastrulation protein), 
chordin-like, DAN/Cerberus-protein family (including Dan, Cerberus, Gremlin, Dante 
and protein related to Dan and Cerberus PRDC), sclerostin, follistatin and follistatin 
related protein (FSRP). Many of these antagonists form high affi  nity complexes selectively 
with the BMPs and inhibit their biological functions. Th ey play an important role 
during the Xenopus embryonic development in establishing a proper BMP-morphogen 
gradient [94]. For example, Noggin, that was fi rst identifi ed as a regulator of the dorsal 
development in Xenopus embryos [95], is an inhibitory binding protein for BMP-2, -4, 
and -7 as well as GDF-5 [96-99]. Chordin also binds BMP-2, -4 and -7 and antagonizes 
their signalling through preventing their binding to the BMP receptors [100]. Proteins 
belonging to the DAN/Cerberus family bind the BMPs similarly to noggin and chordin. 
Follistatin binds activin with very high affi  nity and BMP ligands (BMP-2, -4, -7 and -15/
GDF-9B) as well as GDF-11 with lower affi  nity [23, 101-104]. Follistatin binds activin 
preventing its binding to the receptor, and binds the BMP receptors through the BMPs, 
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thus forming a trimeric complex [102]. Inhibin is a member of the TGF-  superfamily 
and a naturally occurring antagonist of activin. Inhibin antagonizes activin action in the 
pituitary gonadotropes through binding to the activin receptors ActRIIA and ActRIIB 
thereby blocking activin binding [105].
3.2. Intracellular modulators
Th e basal levels of Smad proteins are regulated post-translationally through a 
ubiquitin-mediated proteasomal degradation pathway. Both the size of the Smad pool in 
unstimulated cells and the levels of activated Smads are thus regulated. E3 ligases, Smurf1 
and -2 as well as SCF/Roc1 antagonize TGF-  family signalling through interaction with 
R-Smads, targeting them for degradation and terminating Smad-mediated signalling [106-
108]. Th erefore, Smurf-mediated degradation regulates R-Smad levels and the sensitivity 
of cells to incoming signals. 
In contrast to the R-Smads, expression of the inhibitory Smad6 or Smad7 is highly 
regulated by extracellular signals. Induction of Smad6 and Smad7 expression by BMP and 
TGF-  represents an auto-inhibitory feedback mechanism for ligand-induced signalling 
[6, 109]. Recruitment of a complex of Smad7 with either Smurf1 or Smurf2 to the type I 
TGF-  receptors at the cell membrane results in receptor ubiquitination and degradation. 
Internalization of the receptor complex bound to Smad7 via lipid raft caveolin-positive 
compartments promotes poly-ubiquitination and results in accelerated receptor turnover 
[82]. Activation of the EGF receptor and possibly other tyrosine kinase receptors, 
interferon-  signalling through STAT (signal transducer and activator of transcription) 
proteins, and activation of NF-KB by tumour-necrosis factor-  (TNF ), also induce 
Smad7 expression [88]. 
In addition to the Smurfs, inhibitory Smad6 and Smad7 also modulate the Smad-
mediated signalling. Smad7 inhibits both TGF-  and BMP pathway Smad activation 
through interaction with the type I receptor, whereas Smad6 blocks only BMP pathway 
Smads by competing with the activated R-Smads for heteromeric complex formation with 
Co-Smad4 [110]. Th e co-repressors c-Ski and SnoN are two highly conserved members of 
the Ski family of proto-oncoproteins and they can antagonize TGF-  signalling through 
direct interactions with Smad4 and the R-Smads inhibiting transcription of target genes 
[111, 112].
Dephosphorylation of the Smads by specifi c phosphatases is a mechanism for the 
termination of Smad signalling. PPM1A/PP2C  was recently found to function as a 
Smad phosphatase and to play a critical role in terminating TGF-  signalling through 
dephosphorylation of Smad2 and Smad3 [113]. Th erefore, phosphorylation of the Smads 
not only causes their activation but also modulates their activity and provides a mechanism 
for integration of the Smad pathway with other signalling pathways that can modulate 
TGF-  superfamily signalling.
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4. Folliculogenesis and TGF-  superfamily members in ovarian 
function
Th e principal function of the female gonad is the production of the mature oocyte 
for fertilization and proliferation. Th erefore, the establishment of the germ line that gives 
rise to the oogonia and ultimately the oocytes is of fundamental importance for animal 
reproduction. It was long thought that the oocyte plays a passive role during folliculogenesis, 
but over the past decade or so, this view has changed dramatically. Th e oocyte is now 
known to secrete factors that regulate the diff erentiation and growth of the surrounding 
somatic cells, promoting follicle growth. In response, the somatic cells secrete factors that 
modulate oocyte development. One example of this bi-directional communication is the 
oocyte secreted factor-Kit ligand regulatory loop. Th e immature oocyte produces factors 
that stimulate Kit ligand secretion in granulosa cells [114]. Kit ligand binds to the c-kit 
receptors on the oocyte and promotes oocyte growth [115]. As the oocyte reaches full 
size, the stimulatory eff ect turns to inhibition of Kit ligand synthesis [114]. Th erefore, the 
oocyte modulation of granulosa cell function is developmentally regulated. 
4.1. Ovarian organogenesis
In mice ovarian organogenesis begins when the extraembryonic ectoderm induces 
germ cell determination [116]. During the early embryonic development, uncommitted 
epiblast cells in the extra-embryonic mesoderm involute through the primitive streak to 
the yolk sac endoderm and become committed as primordial germ cell (PGCs) [117]. 
Th ese cells proliferate and migrate via the yolk sac into the hind gut endoderm and 
dorsal mesentery, and fi nally to the genital ridges during gastrulation. As they reach their 
destination, PGCs lose their motility, become encapsulated by the primary sex cords and 
diff erentiate depending on the available sex chromosomes into oogonia or spermatogonia 
[118]. Th e cortical sex cords give rise to the female ovaries, [119] whereas the medulla 
slowly breaks down (reviewed in [77]). 
Th e process of gametogenesis starts as the PGCs leave the dorsal mesentery and 
continues as they enter and colonize the genital ridges to establish the prospective gonad. 
Gametogenesis involves the transition of PGCs into oogonia, which undergo further 
DNA replication until they fi nally enter meiosis to become oocytes. In the developing 
gonads, the oogonia become surrounded by mesonephros derived somatic cells and form 
cortical cords or clusters of germ cells. Individual primordial follicles, where the oocyte 
is surrounded by a unilayer of squamous (pre)granulosa cells and a basal lamina, emerge 
from the distal ends of the cortical cords concomitantly with the initiation of meiosis 
(reviewed in [77, 118-120]). 
In humans, the ovaries start to form during the fi rst weeks of gestation, and oogonia 
appear around the 6th to 7th week of gestation. Th e oogonia fi rst divide mitotically and 
colonize the primitive ovary. Oogonia become oocytes as they enter meiosis, and by the 
20th week of gestation the number of oocytes is at the greatest (6-7 million). Th e pool of 
oocytes slowly diminishes, and at birth only 300 000-400 000 oocytes remain enclosed 
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within follicles [121, 122]. At puberty, only two hundred thousand primordial follicles 
are left [123]. Of these, only about 400 are ovulated during reproductive life while the rest 
undergo atresia. By menopause, which today occurs in most women at the age of ~51, the 
ovarian reserve of primordial follicles is depleted. 
4.2. Overview of ovarian folliculogenesis
4.2.1. Gonadotropin-independent growth
Th e pool of primordial follicles within the ovaries remains dormant until the onset 
of puberty, although some follicles are continuously recruited to the growth phase. 
As primordial follicles undergo transition into primary stage, the size of the oocyte 
increases and the somatic pregranulosa cells around the oocyte become cuboidal and are 
thereafter termed granulosa cells [118, 120]. When two or more layers of granulosa cells 
have developed, the follicles are called secondary or preantral follicles. Granulosa cells 
proliferate very slowly at the early stages of folliculogenesis: in humans the transition 
from the primary to the secondary follicle stage may take as long as 120 days [124]. 
At the secondary stage, the oocyte grows extensively, the granulosa cells become more 
proliferative and a theca cell layer is recruited from interstitial stromal cells to surround the 
follicle outside the basal lamina. Th e presence of the oocyte in preantral follicles inhibits 
granulosa cell progesterone synthesis and premature luteinization [125]. Multilayered 
follicles are poorly vascularized, since the basal lamina inhibits the intrusion of blood 
vessels from thecal layers to the granulosa cell layer. 
Oocyte growth is required to achieve meiotic competence and for the oocyte to be able 
to resume nuclear maturation needed for fertilization and cell cleavage. During the growth 
phase, the oocyte also diff erentiates and secretes a glycoprotein rich membrane, the zona 
pellucida, that coats the oocyte. Granulosa cells become coupled with each other as well as 
with the oocyte via gap junctions passing through the newly formed zona pellucida [126]. 
Th e gap junctions facilitate the bi-directional communication between the oocyte and 
granulosa cells and allow the transfer of small molecules. 
As folliculogenesis proceeds, a fl uid fi lled antrum is formed within the multilayered 
granulosa cells. Antrum formation divides the granulosa cells into two distinct 
compartments, the cumulus granulosa cells closely surrounding the oocyte and the mural 
granulosa cells lining the follicle wall within the basal lamina (see Figure 4). Folliculogenesis 
may proceed from primordial follicles through primary and secondary stages into early 
antral stage independently of the gonadotropins, despite the fact that granulosa cells gain 
responsiveness to FSH already at the secondary follicle stage in humans when they begin 
to express FSH receptors [127].
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4.2.2.  Gonadotropin-dependent growth
Th e default pathway of an ovarian follicle is to undergo atresia at the early antral 
stage, but as levels of circulating FSH rise at puberty, a few antral follicles are rescued 
from atresia by FSH and are recruited to continue growth during each menstrual cycle. 
One of the growing follicles becomes chosen as the dominant follicle that develops into 
a mature Graafi an follicle competent of fertilization while the rest undergo atresia. At the 
antral stage, the theca cells diff erentiate into theca externa and theca interna. Th ey begin 
to express LH receptors and produce androgens under the infl uence of LH. Granulosa 
cells of selected follicles continue to express FSH receptors and begin to express LH 
receptors (FSHR and LHR, respectively) as well as P450 aromatase, gaining the ability 
to produce estrogen from thecal androgens. Among the recruited follicles the leading 
follicle grows faster and produces higher levels of estrogens and inhibins than the rest. 
Th e expression of follistatin, an activin antagonist, is also upregulated during the antral 
phase and causes a shift in the activin/inhibin balance towards inhibin. Together, estrogens 
and inhibins produced by the largest follicle suppress pituitary FSH production and as a 
result the remaining selected follicles are deprived of adequate FSH stimulation required 
for survival. After antrum formation the two granulosa cell compartments diff erentiate. 
Mural granulosa cells continue to express LH receptors and produce progesterone at low 
levels, while the cumulus cells surrounding the oocyte have a low steroidogenic capacity 
and a high proliferative activity. In addition, the oocyte secretes factors that suppress LHR 
expression in the cumulus cells. At the antral stage the immature oocyte has completed its 
growth and is competent to resume meiosis (reviewed in [119, 124]).
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4.2.3. Ovulation and corpus luteum formation
It has been estimated that the transition from the primary to the secondary follicle 
stage takes more than 120 days in humans. In addition, the secondary follicle develops 
into an antral follicle in 71 days and from this stage the development to a preovulatory 
stage takes a further 14 days [124]. Th e last seven days before ovulation are marked with 
an increased growth of the dominant follicle. Th e LH surge triggers the onset of the 
ovulation process and within ~36 hours the follicle wall ruptures and the oocyte is released 
into the peritoneal cavity. During the ovulation process, the gap junctions between the 
oocyte and granulosa cells are disrupted and the oocyte undergoes a series of changes in 
its nucleus as well as in the cytoplasm, known as oocyte maturation. Oocyte meiosis is 
resumed and arrested again at Meiosis II until fertilization. 
Th e LH surge also shifts the granulosa steroid production from estrogen to progesterone 
and induces the cumulus granulosa cells to secrete a hyaluronic acid rich extracellular matrix 
in a process called cumulus expansion. Th is matrix is important for oocyte extrusion from 
the follicle and for ovum pick-up by the oviduct fi mbria. Biochemically, the ovulation 
process resembles an acute infl ammation, as eicosanoids, prostaglandins and proteolytic 
enzymes are upregulated and play a role in rupturing the follicle wall. 
Th e remaining follicle degenerates into a corpus luteum after ovulation. Vasculature 
and fi broblasts from the surrounding theca cell layers penetrate the basal lamina and the 
mural granulosa cells begin the uptake of cholesterol and luteinize. Th e main function 
of the corpus luteum is to produce progesterone under the infl uence of LH. Th e corpus 
luteum maintains steroid production for 14±2 days after which it declines into avascular 
corpus albicans if pregnancy does not begin. 
4.3. TGF-  superfamily ligands in folliculogenesis
Within the ovary, the progress of folliculogenesis is in part regulated by peripheral 
endocrine factors, the pituitary gonadotropins FSH and LH as well as growth hormone 
(GH) and prolactin in some species. In addition, intraovarian factors, such as steroids, 
cytokines and other growth factors act in a paracrine/autocrine manner and co-ordinately 
contribute to the processes of recruitment, development, atresia, selection and ovulation 
of follicles. Th e growth of the follicle is considered to be gonadotropin-independent to 
the small antral stage and during these early phases folliculogenesis is considered to be 
driven by these local autocrine and paracrine signals from the oocyte and the surrounding 
somatic cells [77]. 
A complex bi-directional communication axis between the oocyte and granulosa cells as 
well as between the granulosa and thecal cells drives the progression of follicle development 
at these early stages. Five diff erent classes of growth factors, including insulin-like growth 
factor (IGF), TGF- , TGF- , fi broblast growth factor (FGF) and cytokines have been 
described within human ovarian follicles. 
Th e role of TGF-  superfamily ligands in ovarian organogenesis as well as 
folliculogenesis has been studied extensively in animals. From these studies it is known 
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that various TGF-  superfamily members are expressed by the oocyte, granulosa and theca 
cells in a developmental-stage related manner. Among the local factors at least activins, 
inhibins, TGF- s, BMPs, growth diff erentiation factor 9 (GDF-9) and GDF-9B (also 
known as BMP-15) as well as AMH (also known as Müllerian inhibiting substance, MIS) 
are required during the development of follicles [119]. Th e developing oocyte is known to 
express BMP-6, GDF-9 and its close homolog GDF-9B [17, 18, 128]. Recently, Dragovic 
et al. discovered that oocytes from preovulatory mouse follicles also express inhibin A 
and B subunit mRNAs, although the secretion of the respective proteins remains to be 
further studied [129]. Th e granulosa cells produce at least activins, inhibins, TGF- s, 
BMP-2, BMP-3 and BMP-6 as well as AMH at diff erent stages of folliculogenesis, while 
the theca cells can produce all the isoforms of TGF- , BMP-3b, BMP-4 and BMP-7 [130, 
131] (reviewed in [77]).
For appropriate signalling, an intact signalling cascade from ligands and receptors 
to intracellular eff ectors and accessory proteins has to be present and functional. Th e 
temporal and spatial regulation of these signalling cascade molecules determines the 
responsiveness of the cell type to each stimulus and the direction of signalling within the 
follicle is dependent on cellular distribution of the whole signalling pathway. Of the TGF-
 superfamily ligands particularly the BMPs together with their antagonists have been 
shown to play a prominent role throughout embryonic development and organogenesis. 
Gene ablation studies in mice have identifi ed BMP4, -8b and -2 as regulators of 
primordial germ cell (PGC) formation from the epiblast cells [2]. Targeted mutations of 
either BMP-4 or BMP-8b lead to severe defects in PGC formation in the embryos that 
survive gastrulation [2]. In addition, reproductive defects have been found in knockout 
mice for diff erent ovary expressed TGF-  superfamily signalling proteins, such as activin 
B, GDF-9B/BMP-15, GDF-9, AMH, ALK6, AMHRII, inhibin  and Smad3 [2, 3] 
(reviewed in [77]). 
5. Oocyte-secreted growth differentiation factors 9 and 9B
5.1. GDF-9 gene and protein structure
GDF-9 was fi rst discovered in 1993 in search for new TGF-  related sequences from 
mouse genomic DNA [16]. Th e mouse GDF-9 gene is encoded by two exons separated 
by a 2.9 kb intron  and codes for a 1.7 kb messenger RNA (mRNA) [132]. Th e GDF-9 
gene localizes to the autosomal chromosome 11 in the mouse (11 B1.3; 11 29.0 cM) and 
chromosome 5 in the human (5q23-5q33.1). Th e predicted amino acid sequence of mouse 
GDF-9 shows a predicted signal peptide of 29 amino acids in the  N-terminus (determined 
by SignalP 3.0 Server; http://www.cbs.dtu.dk/services/SignalP), followed by a 277 aa pro-
region that contains a tetra-basic proteolytic processing site at position 303-306, and a 
135 aa C-terminal mature region that shows signifi cant sequence similarity with known 
TGF-  superfamily members [16]. Th e mouse GDF-9 pro-peptide contains four potential 
N-glycosylation sites at asparagines 163, 229, 258 and 325. GDF-9 lacks the fourth out 
of seven conserved cysteine residues in the C-terminal region [16] that is required for the 
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formation of a covalent dimer, a characteristic of most TGF-  superfamily ligands [14, 
15]. Th erefore, GDF-9 may only form dimers through noncovalent interactions. 
In most mammalian species, GDF-9 transcripts and protein are expressed specifi cally 
in the  growing oocytes from the primary follicle stage onwards until fertilization [133-
138]. In bovine and ovine ovaries, GDF-9 transcripts can, however, be detected already in 
primordial follicles [139]. Fitzpatrick et al. have reported GDF-9 mRNA expression also 
in non-ovarian tissues such as testis and hypothalamus [140], but its function in these 
organs remains unclear. 
5.2. Transcriptional regulation of GDF-9
Recently, regulatory elements  that confer high-level expression of GDF-9 in the oocyte 
were reported by Yan et al. [141]. Th e proximal ~400 base pairs upstream of the GDF-9 
gene in several mammalian species contain a conserved E-box sequence (CAGCTG) that 
enables oocyte-specifi c expression of GDF-9 [141]. E-box sequences have been identifi ed 
in several tissue-specifi c gene promoters, and they are involved in tissue specifi c protein 
expression through binding basic helix-loop-helix (bHLH) transcription factors [142, 
143]. Figla, also known as Fig- , (Factor in the germline alpha) is a germ cell specifi c 
transcription factor that binds to the E-box motif present e.g. in the promoter of oocyte 
specifi c zona pellucida genes together with another transcription factor E12, and regulates 
the expression of ZP1-3 proteins [144]. As of yet, it is not known, however, which factor 
or factors regulate the onset of GDF-9 expression in the oocyte. 
Germ cell nuclear factor (GCNF) is a member of the nuclear receptor superfamily 
that functions as a transcription factor to repress target gene transcription. Both the 
GCNF mRNA and protein are expressed in the oocyte at the primary, secondary and 
pre-ovulatory stages but not in primordial follicles in the adult mouse [145]. GCNF 
recognizes a direct repeat of an AGGTCA-sequence with zero base pair spacing (DR0) 
[146] and can bind to the DR0 elements on the GDF-9 promoter repressing GDF-9 
gene transcription [147]. In oocyte specifi c GCNF knockout mice (GCNFfl/flZp3Cre), 
GDF-9 as well as its homologue GDF-9B are up-regulated during diestrus due to lack of 
GCNF repression [147].
5.3. GDF-9B gene and protein structure 
A close homolog of GDF-9 was discovered fi ve years after the discovery of GDF-9 
simultaneously by two research groups using homology-based cloning approaches. Th is 
growth factor was named GDF-9B (or BMP-15), and it is also expressed in the oocyte 
from the primary follicle stage continuing through ovulation [17, 18]. Th e gene encoding 
for mouse GDF-9B maps adjacent to the centromere on the X-chromosome, and to 
Xp11.2 in the human X-chromosome [18, 133]. Th e mouse GDF-9B gene consists of 
two exons separated by a 4.2 kb intron, coding for a 392 aa pre-pro-peptide consisting of 
a 25 aa N-terminal signal peptide (predicted by SignalP 3.0 Server; http://www.cbs.dtu.
29
dk/services/SignalP), followed by a 242 aa pro-domain and a C-terminal 125 aa mature 
domain. Th e biologically active mature protein is cleaved from the pro-domain at the 
tetrabasic proteolytic cleavage site (residues 264-267) during protein processing. Th ere are 
fi ve potential N-glycosylation sites in the mouse GDF-9B protein located at asparagines 
85, 213, 236, 349 and 373. GDF-9B, like GDF-9, contains only six out of the seven 
conserved cysteines present in the mature domain of most TGF-  superfamily ligands, 
and also in GDF-9B the missing cysteine residue is replaced by serine residue [17, 18]. In 
addition, the mature mouse protein contains two additional cysteine residues upstream 
from the fi rst conserved cysteine like the TGF- s and activins.
6. Biological functions of GDF-9 and GDF-9B
6.1. GDF-9 Knockout mouse
Soon after the discovery of GDF-9, a knockout mouse model was created to defi ne its 
roles in mammalian development. Th e knockout model showed that GDF-9 is essential 
for normal ovarian folliculogenesis as the knockout mice display arrested follicular 
development at the primary follicle stage and are completely infertile while heterozygous 
females and male knockout mice are not aff ected [134]. Th e transition of primordial 
follicles to primary follicles is not impaired in GDF-9 defi cient mice, however, suggesting 
that GDF-9 may not be required for the onset of growth. 
GDF-9 defi cient mice exhibit severe defects in folliculogenesis; the oocyte 
diff erentiation is compromised and the oocytes grow more rapidly compared to control 
oocytes whereas the follicle growth ceases at the primary stage [148]. Although the oocytes 
can achieve full size, their meiotic competence acquisition is impaired and they present 
several ultrastructural abnormalities. Th e granulosa cells surrounding the oocyte do not 
proliferate, but also fail to undergo apoptosis [134]. Th e theca cell layer fails to form, which 
is confi rmed by the absence of several theca cell markers [149]. In addition, the knockout 
mice have elevated serum FSH and LH levels [134]. Molecular characterization of the 
defects in GDF-9 defi cient mouse ovarian follicles has revealed that the primary follicles 
demonstrate an up-regulation of inhibin  and Kit ligand, suggesting that GDF-9 inhibits 
Kit ligand expression in granulosa cells in a paracrine manner [149]. Interestingly, in mice 
lacking both GDF-9 and inhibin , folliculogenesis progresses further than the primary 
follicle stages, and  follicles with multiple granulosa cell layers can be found before the 
mice develop ovarian tumours (late preantral stage). Th is suggests that the granulosa cells 
may proliferate even without the presence of GDF-9 and that up-regulation of inhibin 
prevents the granulosa cell proliferation in GDF-9 knockout mice [150]. In addition, the 
follicles of GDF-9/inhibin  knockout mice become surrounded by a theca cell like layer 
although no theca cell markers can be found, indicating that theca cell recruitment can 
occur but their diff erentiation is blocked. Also their inhibin A and B subunit as well as 
Kit ligand expression is up-regulated [150]. 
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6.2. GDF-9 functions in pre-antral follicles 
Vitt et al. have shown that intraperitoneal (ip) injection of recombinant GDF-9 in 
vivo stimulates primordial and primary follicle progression in mice and increases the 
expression of CYP17 (cytochrome P45017  hydroxylase/lyase), a theca cell marker in 
ovarian homogenate [151]. CYP17 is an enzyme involved in the steroidogenesis of thecal 
androgens (see Figure 5). Both IGF-1- and FSH-induced estradiol and progesterone 
production are suppressed by recombinant rat GDF-9 in small and large bovine granulosa 
cells [152]. Injection of porcine GDF-9 gene fragments into prepubertal gilts caused an 
increase in the number of primary, secondary and tertiary follicles concomitantly with 
the decrease in the number of primordial follicles [153]. In the hamster, GDF-9 has been 
shown to enhance primordial and primary follicle formation [154]. In contrast, Nilsson 
and Skinner were unable to show stimulation of the progression of primordial follicles 
in vitro with recombinant GDF-9 but showed that it promoted the early primary follicle 
progression in the rat [155]. 
In human, recombinant rat GDF-9 promotes the growth, development and survival of 
primordial ovarian follicles up to the secondary follicle stage in organ culture [156], and in 
the cow, GDF-9 stimulates the proliferation of granulosa cells from both small and large 
follicles in the presence of IGF-I and FSH [152]. Treatment with recombinant rat GDF-9 
either alone or in the presence of FSH stimulates the growth of preantral follicles isolated 
from immature rats as measured by the follicle diameter [135]. In organ culture, GDF-9 
has been shown to promote human ovarian follicle growth, development and survival 
within thin slices of ovarian cortical tissue [156]. In neonatal rat ovary explants, treatment 
with rat recombinant GDF-9 also enhances inhibin  protein content, a diff erentiation 
marker for early follicles [135]. Recombinant GDF-9 suppresses the diff erently spliced 
Kit ligand (KL) transcripts KL-1 (principally existing in soluble form) and KL-2 (mainly 
membrane bound) expression in mouse preantral follicles [157]. 
Very recently, it was discovered that GDF-9 prevents rat granulosa cell apoptosis 
during preantral to early antral stage by inhibiting the activation of PI-3K/Akt pathway 
[158]. Down-regulation of GDF-9 by morpholino oligonucleotides induced follicle cell 
apoptosis causing an increase in caspase-3 activity and suppressed preantral follicle growth 
in vitro [158]. GDF-9 also protected granulosa cells from ceramide-induced apoptosis 
in early antral follicles but not in late antral or preovulatory follicles. In addition, the 
presence of GDF-9 was required to maintain the FSH receptor mRNA expression during 
preantral to early antral transition [158]. 
6.3. GDF-9 functions in antral follicles
Recombinant rat GDF-9 functions as a granulosa cell mitogen of early antral as 
well as preovulatory rat follicles. It also modulates granulosa cell steroidogenesis by 
suppressing FSH stimulated progesterone and estradiol production [159] but stimulates 
basal steroidogenesis in the absence of FSH [149, 159]. In primary theca cells and 
immortalized theca-interstitial cells, GDF-9 stimulated both basal and LH-induced 
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androstenedione synthesis in vitro [160]. In addition, recombinant GDF-9 suppresses 
FSH-induced LH receptor expression in both antral and preovulatory follicles and FSH-
induced cAMP synthesis in small antral follicles whereas in preovulatory follicles the eff ect 
is smaller [159]. Figure 5 illustrates the steroid synthesis pathways in theca and granulosa 
cells. In human granulosa cells, GDF-9 also inhibits cAMP-induced steroidogenesis in 
preovulatory human granulosa cells [161]. Recombinant GDF-9 suppresses both KL-1 
and KL-2 mRNA expression in mouse mural granulosa cells from antral follicles without 
aff ecting the KL-1:KL-2 ratio  [157]. 
Figure 5. Progesterone and estrogen synthesis pathways. StAR regulates the 
transport of cholesterol into the inner membrane of the mitochondrion, which is 
the rate limiting step in the steroid synthesis pathway. LH regulates the cholesterol 
transport into the mitochondrion. P450scc catalyses the cholesterol side chain 
cleavage within the mitochondrion while the rest of the steroid synthesis pathway 
enzymes are located in the smooth endoplasmic reticulum. FSH stimulates the 
aromatization (P450aromatase action) of thecal androgens into estrogens in 
granulosa cells. (StAR, steroidogenic acute regulatory protein; P450scc, side chain 
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Oocytes are known to secrete factors that promote follicle growth, and GDF-9 can 
partly mimic this oocyte eff ect [162]. A GDF-9 neutralizing antibody mAb-GDF-9-53 
can completely block the GDF-9-induced granulosa proliferation whereas it can only 
partially block the mitogenic activity of denuded oocytes cultured with mural granulosa 
cells [162].
6.4. GDF-9 during cumulus expansion 
Recombinant mouse GDF-9 has been shown to modulate the expression of some 
proteins involved in cumulus expansion therefore mimicking the actions of the 
oocyte. GDF-9 can induce hyaluronan synthase 2 (HAS2), cyclo-oxygenase 2 (COX-
2, prostaglandin endoperoxide synthase 2) and steroidogenic acute regulatory protein 
(StAR) mRNA synthesis and suppresses urokinase plasminogen activator (uPA) and 
LHR mRNA expression in granulosa cells from antral follicles in mice [138]. In addition, 
recombinant mouse GDF-9 can induce cumulus expansion in oocytectomized cumulus-
oocyte complexes (COCs) in the absence of oocytes [138]. HAS2 is expressed in mouse 
cumulus cell-oocyte complexes after gonadotropin surge and just preceding effi  cient 
cumulus expansion and is involved in the synthesis of the hyaluronic acid rich matrix 
by the cumulus granulosa cells during cumulus expansion [163]. Inhibition of uPA, a 
serine protease that cleaves plasminogen into its active proteolytic form plasmin, prevents 
the degradation of this matrix [164]. StAR regulates the transport of cholesterol from 
the outer membrane of the mitochondrion to the inner membrane during progesterone 
synthesis in granulosa cells, whereas COX-2 catalyzes the rate limiting fi rst step in the 
synthesis of prostaglandins (especially prostaglandin E2, PGE2), which may be involved 
in the induction of ovulation, cumulus expansion and implantation [165-167]. GDF-9 
also enhances prostaglandin E2 receptor (EP2) mRNA expression in preovulatory mouse 
granulosa cells, and can stimulate progesterone synthesis through a PGE2–EP2 pathway 
[168]. Down-regulation of LH receptor mRNA expression in the granulosa cells inhibits 
their responsiveness to LH and as a result, luteinization. 
Recently, it was reported that injection of GDF-9 double stranded RNA (RNA 
interference) can block the fully grown mouse oocyte GDF-9 mRNA, but not the GDF-
9B mRNA expression, and also reduce the GDF-9 protein levels [169]. In addition, 
cumulus cells incubated with GDF-9 dsRNA-injected oocytes showed only limited 
cumulus expansion compared to control cumulus cells cocultured with buff er-injected 
and dsGDF-9B-injected oocytes. HAS2 and Ptgs2 (prostaglandin-endoperoxide synthase 
2, COX-2) mRNA levels were downregulated in cumulus cells cocultured with GDF-9 
dsRNA, suggesting that GDF-9 could be the oocyte secreted factor enabling cumulus 
expansion [169]. However, in another study, the specifi c GDF-9 neutralizing antibody 
mAb-GDF-9-53 could not completely neutralize the oocyte-induced cumulus expansion 
of oocytectomized cumulus-oocyte complexes (OOX), although it could neutralize the 
recombinant GDF-9-induced  expansion of the OOX complexes [170]. Also, oocyte 
induced HAS2 expression could not be blocked completely by the antibody, while it could 
attenuate GDF-9-induced HAS2 transcription. Finally, the soluble form of the extracellular 
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domain of BMPRII, the type II receptor for GDF-9 in granulosa cells [42], antagonized 
GDF-9-induced expansion but only partially antagonized the oocyte-induced expansion 
[170]. Th us, the results from Dragovic et al. suggest, that GDF-9 cannot alone account for 
the actions of the oocyte secreted cumulus expansion enabling factor (CEEF). 
6.5. GDF-9 target genes
Only a few direct target genes for GDF-9 have been identifi ed so far in the ovary. 
GDF-9 has been shown to induce HAS2, COX-2 as well as StAR mRNA expression 
and to suppress uPa and LHR mRNA expression in cultured mouse granulosa cells 
[138]. With a microarray approach, Varani et al. found that GDF-9 induces pentraxin 3 
expression in mural granulosa cells of preovulatory mouse follicles and tumour necrosis 
factor-induced protein 6 (TNFIP6) in all granulosa cells after the LH surge [171]. 
Pentraxin is a secretory protein that belongs to the long pentraxin family of infl ammatory 
proteins. It is expressed by the cumulus cells during cumulus expansion and localizes into 
the matrix [172]. Recombinant mouse GDF-9 also induces peroxiredoxin 6 expression in 
bovine cumulus cells [173]. Prostaglandin E2 (PGE2) as well as prostaglandin E2 receptor 
(EP2) expression is also promoted by GDF-9 administration [168]. Recently, Pangas et al. 
identifi ed gremlin, a BMP antagonist, as a gene regulated by GDF-9 in mouse granulosa 
cells from large antral follicles [174]. However, gremlin does not inhibit GDF-9 activity 
although it can suppress the BMP-4-induced prostaglandin E2 production [174].
7. GDF-9B in the ovary
7.1. GDF-9B defi cient mice
GDF-9B-defi cient male mice are normal and fertile, whereas female mice exhibit 
reduced fertility due to defects in the ovulation process and the ability of oocytes to develop 
into normal embryos [175]. A superovulation protocol with the GDF-9B-/- mice revealed 
that some oocytes were trapped within the follicle and were not ovulated. In addition, 
the trapped oocytes were denuded and larger than normal, and were only surrounded by 
a few cumulus cells [175]. Double mutant mice lacking both alleles of GDF-9B and one 
allele of GDF-9 have more severe fertility defects than the GDF-9B knockout. Th ese mice 
display abnormalities in folliculogenesis, cumulus cell function and fertilization [175]. 
7.2. GDF-9B functions in the ovary
Like GDF-9, recombinant GDF-9B functions as a granulosa cell mitogen, promoting 
rat granulosa cell proliferation independent of FSH eff ects [176]. GDF-9B suppresses 
FSH-induced progesterone synthesis while having no eff ect on estradiol production or basal 
steroidogenesis [176]. GDF-9B inhibits FSH-dependent granulosa cell diff erentiation by 
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Figure 6. A schematic drawing of the gonadotropin signalling pathway.
Gonadotropin binding to its transmembrane receptor activates a stimulatory 
G-protein. The Gs -subunit activates adenylyl cyclase (AC) that catalyses the 
conversion of ATP into cAMP. Forskolin is a diterpene and an activator of adenylyl 
cyclase. The second messenger cAMP activates protein kinase A (PKA) which can 
also be activated by a stable 8-Br-cAMP molecule. PKA causes the phosphorylation, 
and therefore the activation or inactivation, of downstream effector proteins 
that regulate target gene expression. CREB is a cAMP responsive element binding 
protein (CREB) that functions as transcription factor and CBP is a protein binding 
CREB. GDF-9 inhibits the expression of the LH receptor in granulosa cells while 
GDF-9B can block the expression of the FSH receptor mRNA.
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suppressing the expression of the FSH receptor mRNA, leading to the suppression of 
FSH-induced increases of StAR, P450scc, P450arom, 3 -hydroxysteroid dehydrogenase, 
LHR and inhibin subunit mRNA expression in rat granulosa cells [176]. FSH binding 
to its transmembrane receptor induces the activation of a stimulatory G-protein which 
in turn activates adenylyl cyclase (AC) (see Figure 6 for a schematic of the gonadotropin 
signalling pathway). AC catalyses the synthesis of a second messenger cyclic AMP from 
ATP, and activation of intracellular protein kinase A (PKA) pathway by cAMP causes the 
phosphorylation of downstream proteins eventually leading to regulation of target gene 
transcription. GDF-9B acts upstream of the cAMP signal since GDF-9B could not inhibit 
forskolin-induced increase of the above mentioned proteins (Figure 6) [176]. Follistatin, 
an inhibitor of activins [101], BMP-2, -4 [102] and -7 [23], can antagonize the GDF-9B 
suppression of FSH receptor expression and attenuate GDF-9B induced granulosa cell 
proliferation by binding directly to the GDF-9B molecule [177].
GDF-9B also stimulates FSH synthesis and secretion in primary culture of rat pituitary 
gonadotrope cells without aff ecting LH and gonadotropin releasing hormone receptor 
(GnRH-R) expression [178]. Both GDF-9 and GDF-9B modulate the expression of Kit 
ligand (KL) in granulosa cells, GDF-9 inhibiting and GDF-9B promoting its expression 
[179]. Kit ligand expression in granulosa cells suppresses the oocyte GDF-9B mRNA 
synthesis, establishing a negative paracrine feedback loop within the follicle [179]. Blocking 
of c-Kit, the oocyte expressed receptor of KL, by a c-kit antibody suppressed the GDF-9B-
induced granulosa cell proliferation, suggesting that the involvement of c-kit signalling 
is important for GDF-9B stimulated granulosa cell mitosis [179]. Oocytes can prevent 
cumulus cell apoptosis in bovine COCs, and the administration of GDF-9B, BMP-6 or -7 
to oocytectomized complexes reduced cumulus cell apoptosis signifi cantly, whereas GDF-
9 had no eff ect [180]. However, follistatin, that antagonizes GDF-9B action [104], or 
BMP-6 neutralizing antibody could only block approximately 50% of the oocyte-induced 
anti-apoptotic eff ect [180]. 
Recently, Yoshino et al. studied the expression pattern of the C-terminal mature 
domain of GDF-9B in mouse ovaries and discovered that the mature form of the protein 
is barely detectable in the oocytes of preovulatory follicles but its expression is signifi cantly 
increased in the oocytes just before ovulation [181]. In addition, GDF-9B was shown to 
induce cumulus expansion and the expression of EGF-like growth factors as well as some 
molecules downstream the EGF signalling pathway in the cumulus cells, including COX2, 
HAS2, pentraxin 3 and tumour necrosis factor-induced protein 6 [181]. Interestingly, all 
of these genes have also been found to be upregulated by GDF-9 [138, 171]. Gueripel 
et al. also reported recently that GDF-9B expression is increased during gonadotropin-
induced follicular development and is associated with cumulus expansion in immature 
mice [182]. Th ese results are in line with the fi ndings in GDF-9B knockout mice that 
have defects in the ovulation process, suggesting that GDF-9B plays a major role in the 
cumulus expansion in the mouse. Table 3 below compares the eff ects of GDF-9 and GDF-
9B during the diff erent stages of folliculogenesis.
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8. Naturally occurring mutations in GDF-9 and GDF-9B genes
8.1. Human mutations 
In 2004, a rare deletion mutation in the human GDF-9 gene was described in heterozygous 
sisters with spontaneous dizygotic twins [183]. A four base pair deletion beginning at position 
207 from the start of exon 1 alters the open reading frame and introduces a premature stop 
codon leading to the truncation of the GDF-9 protein in the pro-region and therefore a loss 
of function. Eight single nucleotide polymorphisms (SNPs) were discovered from screening 
the coding region of GDF-9 in a vast sample of mothers with dizygotic twins. However, 
no evidence could be found that these common variations within the human GDF-9 locus 
contributed to the frequency of dizygotic twinning [183]. However, recently Palmer et al. 
found six rare novel variants in GDF-9 in mothers of dizygotic twins [184]. Th e novel 
variants are signifi cantly more common in mothers of dizygotic twins suggesting that rare 
GDF-9 variants may contribute to the likelihood of dizygotic twinning [184].
Screening of women with premature ovarian failure (POF) has also revealed mutations 
in the GDF-9 gene [185, 186]. POF manifests itself in malfunction of the whole ovary, and 
is a cause of female infertility. Its symptoms include loss of functional follicles in women 
under 40 years of age, amenorrhea for at least 6 months and high gonadotropin levels 
and low estrogen levels [187]. Two missense mutations have been found in Indian women 
(substitution of lysine for glutamate, K67E; and of valine for methionine, V216M) and one 
in a patient of Caucasian origin (substitution of serine for tyrosine, S186Y), which were 
associated with POF [185, 186]. All of these mutations were found in the pro-region of 
the protein. Takebayashi et al. failed to identify mutations in human GDF-9 or -9B genes 
in POF and polycystic ovary syndrome patients (PCOS) but this may be due to a limited 
sample size used in the study (15 patients with POF and 38 patients with PCOS) [188].
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Mutations in the human GDF-9B gene have also been identifi ed in patients with POF. 
Th e fi rst human mutation was described in sisters with hypergonadotropic ovarian failure 
due to ovarian dysgenesis (OD) [189]. A heterozygous non-conservative substitution in the 
second exon causes the substitution of a tyrosine residue for a cysteine within the GDF-9B 
pro-region (Y235C). Th e mutant protein seemed to be processed abnormally, which may 
be caused by the cysteine substitution that could aff ect the protein dimerization [189]. 
Recently, several missense substitutions in the human GDF-9B gene have been found 
in POF-patients as well, suggesting that the GDF-9B gene is highly associated with the 
etiology of ovarian failure [190, 191]. All of the described mutations are located across 
the pro-region of GDF-9B, as in the case of GDF-9. In six cases the substitution involves 
an arginine residue, but the signifi cance of this is currently unknown (see Table 4 for a 
summary of naturally occurring human mutations in both GDF-9 and GDF-9B).
Table 4. Naturally occurring mutations in human GDF-9 and GDF-9B genes possibly 
affecting the ovarian phenotype. (POF, premature ovarian failure; SA, secondary 
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A naturally occurring mutation in the GDF-9 gene was recently discovered in the 
Belclare and Cambridge sheep strains. Th e mutation  causes sterility and primary ovarian 
failure in homozygous ewes due to abnormal follicle development but an increased 
ovulation rate and fertility in heterozygotes compared to wild-type sheep [192]. Th is 
mutation (named FecGH) changes an uncharged polar serine residue in the GDF-9 mature 
domain into a nonpolar phenylalanine located in a region that is predicted to be involved 
in type I receptor binding, possibly aff ecting the ability of the mutated GDF-9 to bind 
to its receptor [192]. Some antral follicles have been found in the mutant ewe ovaries but 
the oocytes in this stage follicles are often degenerated, and also the arrangement of the 
granulosa and cumulus cells are irregular and abnormal [193]. 
Five diff erent mutations in the GDF-9B gene have been discovered in sheep that aff ect 
fertility and ovulation rate. All these mutations cause an arrest in folliculogenesis at the 
primary follicle stage in homozygous animals resembling the phenotype of the GDF-9 
knockout mouse. In contrast, heterozygous ewes for the individual GDF-9B mutations 
exhibit increased ovulation rates and fertility. Most GDF-9B mutations are located in the 
mature region of the protein, but the FecXG mutation causes a premature stop codon in 
the proregion and therefore no bioactive mature protein can be produced. Table 5 below 
lists the known mutations in the sheep GDF-9 and GDF-9B genes that aff ect fertility and 
ovulation rate.
Th ere is a clear discrepancy between the phenotypes of the homozygous GDF-9B 
knockout mice that are only subfertile and the completely infertile GDF-9B mutant ewes 
but the reason for this diff erence is not fully understood. It has been suggested however, 
that the diff erences may derive from the low- vs. poly-ovulatory nature of these species, 
or the diff erent relative importance of these growth factors in sheep and mice [175, 194]. 
In contrast, a mutation in the human GDF-9B gene located in the proregion was found 
recently in two sisters with hypergonadotropic ovarian failure [189]. Th e patients had 
streak ovaries resembling the homozygous GDF-9B mutant sheep ovaries.
Th e eff ect of gene dosage of GDF-9 and GDF-9B can be mimicked by 
immunoneutralizing the GDF-9 and GDF-9B proteins. Short term immunization of 
sheep against either GDF-9 or GDF-9B using a DEAE dextran adjuvant (low effi  cacy 
immunization) can lead to an increased ovulation rate having no apparent harmful eff ects 
on fertilization of the released oocytes or subsequent pregnancy [195]. In contrast, long 
term immunization with an adjuvant causing a strong immune response (i.e. Freunds 
adjuvant) can result in abnormal follicular development and anovulation [196]. In sheep, 
both GDF-9 and GDF-9B have been shown to be important for the follicular development 
unlike in mice, and in addition, ovulation rate in sheep is dependent on the changes in the 
dosage of either of these factors.
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Table 5. Naturally occurring mutations in sheep GDF-9 and GDF-9B genes. The 
sheep strains with GDF-9B mutations: FecXG and FecXB alleles are found in Belclare 
Cambridge strains; FecXI Inverdale; FecXH Hanna; FecXL Lacaune. GDF-9 mutation 
FecGH is found in Cambridge and Belclare sheep strains.
9. GDF-9 and GDF-9B protein processing
Liao et al. have demonstrated that human GDF-9 and GDF-9B can readily form 
noncovalently linked homodimers when expressed individually and heterodimers 
when co-expressed [201]. Th e proproteins of the co-expressed GDF-9 and GDF-9B in 
the heterodimer, however, seem to be less susceptible to proteolytic cleavage, since less 
mature GDF-9/GDF-9B protein is secreted compared to singly expressed proteins [201]. 
Introduction of the sheep FecXI (substitution of valine residue at position 31 for aspartate, 
V31D) or FecXB (substitution of serine residue 99 for isoleucine, S99I) mutation into 
human GDF-9B protein weakens the processing effi  ciency of the proprotein compared 
to wild type when expressed alone, and severely reduces or abolishes the processing and 
secretion of the mutant GDF-9B when co-expressed together with human GDF-9 [201, 
202]. Also, the processing of the co-expressed GDF-9 proprotein into mature protein 
is simultaneously impaired [201]. When human GDF-9 protein carrying the sheep 
mutation FecGH (substitution of serine residue 77 for phenylalanine, S77F) was co-
expressed with mutant GDF-9B, the secretion of both proteins was signifi cantly reduced 
[202]. An interesting observation was made by Hashimoto et al. that interactions between 
the proregion and the mature protein of mouse GDF-9B seem to prevent the proper 
processing of the proprotein [203] as no mature protein is produced. Th e mouse proregion 




















































Th e aims of this thesis project were to uncover the signalling components of the 
oocyte growth factor GDF-9. We wanted to study whether GDF-9 can signal through 
the canonical TGF-  superfamily pathway or whether it utilizes some other receptor-
intracellular mediator molecules.
Specifi c aims were:
• To develop a cell model for studying the TGF-  superfamily signalling   
 components in ovarian context (I)
• To study the eff ect of GDF-9 on inhibin B production in human 
 granulosa cells (II)
• To determine whether either the Smad2/3 or the Smad1/5/8 pathway is   
 activated by GDF-9 (II)
• To determine the type I and II receptors involved in the signalling of 
 GDF-9 (III and IV)
AIMS OF THE STUDY
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Please refer to the individual studies (I-IV) for more detailed protocols.
1. Human granulosa-luteal cells
Human granulosa luteal cells used in these studies were obtained by follicular 
aspiration from patients undergoing infertility treatments in Finnish infertility clinics 
Family Federation of Finland, Felicitas IVF Clinic and Department of Obstetrics and 
Gynaecology University of Helsinki. Th e ovaries were stimulated by administrating a 
human GnRH analog and human recombinant gonadotropin. Th irty-six to thirty-seven 
hours prior to oocyte retrieval the patients were administered a total dose of 10 000 IU 
of hCG. Th e granulosa cells from 1-6 patients aspirated the same morning were pooled, 
enzymatically dispersed with 1% hyaluronidase in Dulbecco’s Modifi ed Eagle’s Medium at 
37°C for 30 min. Separation of the granulosa-luteal cells from erythrocytes was achieved 
by centrifugation through Ficoll-Paque. After this the cells were either recovered for RNA 
extraction or plated on plastic culture dishes at densities specifi ed in studies I-IV and 
cultured in DMEM supplemented with 10% fetal calf serum (FCS), 2mM L-glutamine, 
100 IU/ml penicillin, 100 μg/ml streptomycin at 37°C in a 95% air – 5% CO2 humidifi ed 
environment.
2. Rat granulosa cells
Granulosa cells were obtained from small antral follicles of estrogen-treated rats. 
Ovaries were punctured in L-15 Leibovitz medium. Ovarian debris, oocytes, and small 
follicles were removed, and the remaining medium containing granulosa cells was collected 
after low-speed centrifugation at 500 × g for 10 min. Granulosa cells were resuspended 
into the culture medium (McCoy’s 5a supplemented with 2 mM L-glutamine, 100 U/ml 
penicillin, and 100 μg/ml streptomycin).
3. Cell lines
Human embryonic kidney 293T cells and COS7 cells (originating from African green 
monkey kidney fi broblast-like cells) were grown in DMEM whereas P19 cells (derived 
from mouse embryonic carcinoma cells) were cultured in -MEM supplemented with 
10% FCS, 2mM L-glutamine, 100 IU/ml penicillin, 100 μg/ml streptomycin at 37°C in 
a 95% air - 5% CO2 humidifi ed environment in standard 175 ml plastic cell culture fl asks 




Immature female rats (Sprague-Dawley, 25 d old, body weight from 50–60 g) were 
obtained from Charles River Laboratories (Wilmington, MA). Animals were anesthetized 
and killed using CO2 72 h after insertion of diethylstilbestrol implants. All animals were 
housed under controlled humidity, temperature, and light regimen and fed ad libitum on 
a standard rat chow. Animal care was consistent with institutional and National Institutes 
of Health guidelines.
5. Expression of mouse and rat recombinant GDF-9
Tagged and untagged recombinant rat GDF-9 protein has been previously described 
[135]. A cell line expressing fully processed mouse GDF-9 was also developed and used as 
a source of bioactive recombinant GDF-9 protein. Th e mouse full-length cDNA [17] was 
subcloned into pEFIRES-P expression vector [204] and transfected into HEK 293T cell 
line by FuGene 6 (Roche Diagnostics) transfection reagent. Cells expressing high levels 
of the recombinant protein were selected with increasing concentrations of puromycin 
in DMEM supplemented with 10% FCS, 2 mM L-glutamine, 100 IU/ml penicillin, 
100 μg/ml streptomycin and 0.25 μg/ml amphotericin B. Th e recombinant protein was 
produced into serum-free harvesting medium (DMEM/Ham’s F-12, 1:1) supplemented 
with L-glutamine and 100 IU/ml penicillin, 100 μg/ml streptomycin and 0.25 μg/ml 
amphotericin B, 0,01% (vol/vol) BSA and 100 μg/ml heparin. Levels of recombinant 
protein were estimated in immunoblots using the purifi ed N-tagged rat GDF-9 as a 
standard [135].
6. Generation of monoclonal antibodies against GDF-9
A synthetic peptide to annotated amino acids 420-450 of the C-terminal part of the 
human GDF-9 of sequence VPAKYSPLSVLTIEPDGSIAYKEYEDMIATKC (GenBank 
accession no. NP 005251) was made using F-moc chemistry, coupled to tuberculin through 
the cysteine thiol using a heterobifunctional agent, and used to immunize mice by standard 
methods. After an initial immunization and two boosts at monthly intervals, the sera of 
the mice collected by tail bleed were tested against ELISA wells coated directly with the 
immunizing peptide. High responding mice were boosted iv, and 4 days later the spleens 
were removed and used for fusion to SP2/0 splenocytes by standard methods. Positive 
hybridomas were tested in Western blot against recombinant GDF-9. Monoclonal antibody 
37 was purifi ed by protein A chromatography using a high salt protocol. Th e antibody has 
minimal cross-reaction with preparations of recombinant GDF-9B/BMP-15.
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7. Expression plasmids and reporter gene constructs
Th e pGL3(CAGA)12-luciferase reporter plasmid was provided by Dr. C. H. Heldin 
(Ludwig Institute for Cancer Research, Uppsala, Sweden) [205]. Th e pGL3(BRE)-luciferase 
reporter plasmid [206] and the expression plasmid pcDNA3-Smad3 were provided by Dr. 
P. ten Dijke (Th e Netherlands Cancer Institute, Amsterdam, Th e Netherlands). pcI-ALK4 
was provided by Dr. A. Klibanski (Massachusetts General Hospital, Boston, MA) and 
subcloned in the pcDNA3 vector (Invitrogen). Th e pcDNA3-ALK1, pcDNA3-ALK2, 
pcDNA3-ALK3, pcDNA3-ALK5, pcDNA3-ALK6, pcDNA3-ALK7, pcDNA3-Smad3, 
pcDNA3-Smad6, and pcDNA3-Smad7 expression plasmids were from Dr. P. ten Dijke 
(Th e Netherlands Cancer Institute, Amsterdam, Th e Netherlands. Th e reporter pGL2 
(GCCG)15-lux was provided by Dr. K. Kusanagi (Japanese Foundation for Cancer 
Research, Tokyo, Japan[207]. 
8. Recombinant adenovirus constructs
High titer stocks of the recombinant Ad-GFP, Ad-(CAGA)9-luciferase, hemagglutin 
(HA)-tagged wild-type Ad-ALK5 and Ad-ALK4, FLAG-tagged Ad-Smad1/2/6/7, 
HA-tagged constitutively active ALK1-7, kinase defective ALK3/4 as well as Ad-LacZ 
adenoviruses were used in these studies. Th e recombinant adenoviruses Ad-CAGA9-
luciferase [208] and the wild-type HA-tagged Ad-ALK5 were provided by Dr. Peter ten 
Dijke (Th e Netherlands Cancer Institute). Th e Ad-ALK4 adenovirus was produced using 
the Transpose-Ad system (Q-Biogene Illkirch, France) based on reference [209].  Th e 
ALK4-coding sequence was obtained from the plasmid pCIAlk4 (ActRIB), provided by 
Dr. A. Klibanski (Massachusetts General Hospital, Boston, MA). 
Th e original cloning and generation of the recombinant Ad-Smad1/2/6/7 as well as 
the constitutively active and kinase defective Ad-ALK-adenoviruses has been reported 
earlier (Fujii et al., 1999). Briefl y, a kit based on a previously described method (Miyake 
et al., 1996) for making recombinant human serotype 5 adenoviruses was purchased from 
Takara Biomedicals (Takara Shuzo Co., Shiga, Japan). Th e respective Smad and ALK 
cDNAs were cloned into the vector pAxCAwt, which contains a potent -actin promoter 
and cytomegalovirus (CMV) enhancers. After preparation of cosmids in competent cells 
(Escherichia coli), co-transfection of the cosmids with adenoviral DNA into 293T cells was 
performed, after which recombinant adenoviruses were generated through homologous 
recombination. Th e recombinant adenovirus vector used lack the E1 and E3 genes needed 
for propagation of the virus. However, these genes are provided by 293T cells, hence the 
adenoviruses can propagate in them. 
9. Adenovirus amplifi cation and purifi cation
For the generation of high titer adenovirus stocks, HEK-293T cells were seeded on 
gelatin-coated culture fl asks (Greiner Bio-One). At 50-70% confl uency (within 1-2 days), 
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the cells were infected with the recombinant adenovirus. Within 2-3 days the cells started 
to detach and show cytopathic eff ects, after which they were harvested and lysed using 
repeated freezing and thawing. Amplifi cation steps were repeated three times and for the 
fi nal round of amplifi cation twelve 175 cm2 culture fl asks were used. Purifi cation of the 
adenoviruses from the fi nal pool of lysed cells was achieved by ultracentrifugation for 
90 min through CsCl gradients of densities 1.3 and 1.6. Th e virus band was retrieved 
and purifi ed using PD-10 columns (Pharmacia) and the fraction containing the virus 
was determined using spectrophotometry. Virus aliquots were stored at -80°C in PBS 
containing 10% glycerol. Titrations of the recombinant adenoviruses were performed in 
293T cells according to the TCID50 method described in the adenovirus manual supplied 
by Takara Biomedicals (http://bio.takara.co.jp/BIO_EN/default.asp). All adenoviral work 
was carried out in a P2 level classifi ed laboratory. 
10. Adenovirus infections
Th e use of recombinant adenoviruses in hGL cultures has been recently optimized 
[210]. We found in these previous studies that cytopathic eff ects are seen when purifi ed 
recombinant adenoviruses are added to hGL cells at multiplicity of infection (MOI) values 
approaching 300. Th ese eff ects are characterized by cellular detachment and death.  
Before adenovirus infection, hGL cells were cultured for 2–3 days. Th e hGL cells were 
infected by incubating with the virus(es) at 37°C in serum-free DMEM supplemented 
with L-glutamine and antibiotics for 1 h, and DMEM containing 2% FCS was added on 
top to stop the infection. Th e cells were then incubated for 24 h before continuing the 
experiments. For details of individual experiments, please refer to the individual studies 
I-IV and references.
11. Transient transfections and luciferase assays
HEK-293T cells were cultured in DMEM supplemented with 10% FCS, 2 mM 
L-glutamine, 100 IU/ml penicillin, and 100 μg/ml streptomycin at 37°C in 5% CO2. 
Th e 293T cells were plated at low confl uence on 24-well plates and grown overnight 
before transfections. Transfections were performed in 0.5 ml medium with 100 ng/well 
(CAGA)12-luciferase reporter construct [205] or the BMP response element (BRE)-
luciferase reporter construct [206] and 10 ng/well -galactosidase reporter plasmid using 
the FuGene 6 transfection reagent Twenty-four hours later the cells were treated with 
TGF- , activin A, BMP-2, or GDF-9 in 1% FCS/DMEM for 24 h. Th e cells were then 
lysed into 1X passive lysis buff er, and luciferase activity was measured with luciferase assay 
reagent (Promega Corp., Madison, WI) and normalized to -galactosidase activity. Data 
are the mean ± SEM of triplicate determinations from representative experiments, relative 
to an adjusted value of 1.0 for the mean of the control wells without ALK4 or ALK5 
adenoviral infection.
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Rat granulosa cells (3 × 105 viable cells/well) were cultured in 24-well plates in 
McCoy’s 5a medium supplemented with 10% FCS for 3 h. After media change, cells were 
incubated in the serum-free medium and transfected with 300 ng of DNA per well using 
Lipofectamine 2000 (Invitrogen). Th e pCMV- -galactosidase plasmid was cotransfected 
to monitor transfection effi  ciency. After transfection, cells were treated with the appropriate 
ligand for 24 h in McCoy’s 5a medium/1% FBS. 
For the siRNA (small interfering RNA) experiments, 250 ng of DNA were transfected 
with or without increasing amounts of siRNAs together with Lipofectamine 2000 
(Invitrogen). Twenty- four hours after transfection, cells were treated with the appropriate 
ligand for 24 h in McCoy’s 5a medium/1% FBS. To harvest cells, lysis buff er (200 μl) 
(Promega Corp.) was added into each well and 30 μl of the supernatant was used for luciferase 
determination using a luminometer (Luminark microplate reader, Bio-Rad Laboratories, 
Inc.). Th e -galactosidase activity was also determined to monitor transfection effi  ciency. 
Th e reporter activity is expressed as the ratio of relative light unit/  galactosidase activity. 
Data are the mean ± SEM of triplicates from representative experiments.
P19 cells were cultured in -MEM supplemented with 10% fetal bovine serum (FBS), 
together with 100 U/ml penicillin, 100 μg/ml streptomycin, and 2 mM L-glutamine. Cells 
were seeded at 60% confl uency in 24-well plates and transiently transfected in -MEM 
for 4 h with 1.8 μg of DNA per well using FuGene-6. After transfection, cells were treated 
with the appropriate ligands for 24 h in -MEM containing 5% FBS. COS7 cells were 
cultured in high glucose DMEM supplemented with 10% FBS, 100 U/ml penicillin, 100 
μg/ml streptomycin, and 2 mM L-glutamine. COS7 cells were seeded at 90% confl uency 
in 24-well plates and transiently transfected in DMEM/ high glucose for 4 h with 1 μg of 
DNA per well using Lipofectamine 2000. 
12. siRNA
Th e siRNAs were chemically synthesized by QIAGEN (Valencia, CA). Th e siRNA 
sequences targeting ALK5 corresponded to the nucleotides 1399–1421 of the rat ALK5 
sequence (Gen- Bank accession no. L26110) 5’-AACAGATGGCAGAGCTGTGAGGC- 
3’. Th e control siRNA 5’ AATTCTCCGAACGTGTCACGT- 3’ was from QIAGEN. 
For annealing of siRNAs, 20 μM single-strand RNA were incubated in the annealing 
buff er [100 mM potassium acetate, 30 mM HEPES-KOH (pH 7.4), 2 mM magnesium 
acetate] for 1 min at 90°C followed by 1 h at 37°C.
13. RNA extraction and preparation of fi lters
Cytoplasmic RNA from freshly isolated hGL cells was extracted with the modifi ed 
Nonidet P-40 lysis procedure [211, 212]. RNA samples were quantitated by absorbance 
measurement at 260 nm. For Northern blots, indicated amounts of RNA were size-
fractionated in 1.5% agarose gels, after which they were transferred to Hybond-N nylon 
fi lters. 
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14. Preparation and labelling of cDNA probes and hybridizations
For the detection of inhibin - and B-subunit mRNAs by Northern Blot 
hybridization, double- and single-stranded cDNA probes were prepared as previously 
described [211, 212]. A human cyclophilin cDNA was used as a loading control for the 
experiment [211]. Northern blot hybridizations were performed for 16 h at 42°C, and 
the fi lters were washed three times for 20 minutes each time with 0.1-1 X standard saline 
citrate/1% sodium dodecyl sulfate at 50°C. Th e fi lters were exposed to a Fujifi lm Ip-reader 
Bio-Imaging Analyzer Bas 1500.
15. Western blotting
Prior to Western blotting, the cells were washed once on ice with PBS, after which 
they were harvested in 1× Laemmli-buff er containing 10% -mercaptoethanol or DTT 
as a reductant. Cells were sonicated on ice for 10 s with a Soniprep 150 MSE sonicator 
(Sanyo Corp., Japan) and boiled for 3 min. Proteins were separated on 10-15% SDS-
PAGE gels and electroblotted onto Hybond-C membranes (Amersham). For the detection 
of hemagglutinin (HA)-tagged ALK receptors a monoclonal rat anti-HA antibody 
(Boehringer Mannheim, Indianapolis, IN, USA; clone 3F10) was utilized, and for the 
detection of FLAG-tagged Smads a monoclonal anti-FLAG antibody (Sigma; clone M2) 
was used. Th e commercial antibodies were used according to protocols provided by the 
manufacturers. For the detection of C-terminally phosphorylated Smad1 and Smad2, -
phospho-Smad1 or -phospho-Smad2 antibodies were used. Phospho-Smad3 antibody 
was provided by Dr. E. Leof (Mayo Clinic, MN).
16. Enzyme-linked immunosorbent assay (ELISA)
Commercial ELISAs for the detection of immunoreactive dimeric inhibin A and B 
in the spent granulosa cell media were used according to the manufacturer’s (Serotec 
Ltd., Oxford, UK) instructions. Th e assays use monoclonal antibodies directed toward 
the human inhibin A- and B-subunits for capture and a Fab alkaline phosphatase 
conjugated monoclonal antibody against the human inhibin -subunit for detection. Th e 
crossreactivity between the two assays is minimal, approximately 0.5% for inhibin A in the 
inhibin B ELISA and < 0.1% for inhibin B in the inhibin A ELISA [213, 214]. A signal 
amplifi cation kit (Life Technologies) was used in connection with the ELISAs. To achieve 
concentrations within the measuring ranges of the assays the spent culture medium was 
diluted with fresh medium.
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1. Granulosa cell model and adenoviruses 
We chose to use human granulosa luteal (hGL) cells as our cell model for studying 
the interactions and biological functions of the TGF-  superfamily ligands and receptors, 
since we had access to these cells through the infertility clinics mentioned earlier in the 
material and methods section. Some granulosa cell lines have been developed from ovarian 
tumours (e.g. the COV434 cell line, [215], and the KGN cell line, which expresses FSH 
receptors and is responsive to FSH [216]), but these were not available for our use when 
this thesis work was started.
Th e hGL cells retrieved from hormone stimulated patients come from pre-ovulatory 
follicles and are as such refractory to further gonadotropin stimulus. However, they 
regain the responsiveness to hCG and FSH after about 2-7 days of culture and produce 
progesterone as well as estradiol under gonadotropin stimulation [217]. Th e human 
granulosa cells have been shown to express the TGF-  superfamily type I receptors ALK2 
[218], ALK3 [219], ALK4 [218] and ALK5 [220]. Also the type II receptors BMPRII 
[219], T RII [220], ActRIIA [218] and ActRIIB [218] as well as Smad1, -2, -3, -4, -5 and 
-6 [219] are expressed in these cells. ALK1 is a TGF- 1 receptor specifi cally expressed in 
endothelial cells [44, 221], and its expression has not been reported in hGL cells. ALK7 
expression has been detected in the ovary, but not reported specifi cally in granulosa cells 
[222]. Th us, most, if not all, of the TGF-  superfamily signalling components are present 
in hGL cells, which makes these cells a good model for studying the mechanisms of TGF-
 superfamily ligand signal transduction in an ovarian setting.
1.1. Adenoviral gene transfer to cultured human granulosa-luteal (hGL) cells
Th e human granulosa luteal cells are terminally diff erentiated and cannot divide 
in culture conditions, although with the addition of special serum these cells may be 
stimulated to proliferate [223]. However, in our hands, the proliferating cells derived 
from the primary hGL cells lost some of their characteristics, such as responsiveness to 
GDF-9 (our unpublished results). Human granulosa luteal cells are also very diffi  cult 
to transfect by conventional methods. Previously, adenovirus-mediated gene transfer has 
been successfully used in cultured rat granulosa cells [224, 225]. We therefore infected 
hGL cells with a recombinant adenovirus that expresses the green fl uorescent protein 
(GFP) under cytomegalovirus (CMV) promoter to fi nd out whether the hGL cells 
were susceptible to adenoviral infection. Twelve hours after the infection, the cells were 
monitored with a fl uorescence microscope (I: Figure 1A-C). Already with multiplicity of 
infection (m.o.i.) values of 1 to 3 many cells expressed GFP. At m.o.i. values above 10, the 
majority of cells were GFP positive. M.o.i. values exceeding 300 caused a cytopathic eff ect 
RESULTS AND DISCUSSION
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due to the adenovirus infection and the cells started to detach and die. Th erefore, m.o.i. 
values between 1 and 100 were chosen for our following experiments. Th us, adenoviral 
transduction provides an effi  cient method to introduce genes of interest also into the hGL 
cells.
1.2. Recombinant adenoviruses
Since their discovery in 1953 [226], adenoviruses have become a versatile model 
for elucidating elementary aspects of gene expression in mammalian cells, leading for 
example to the discovery of mRNA splicing. Today, adenoviruses are commonly used 
as gene transfer vehicles due to their ability to infect a wide range of non-dividing cells. 
Adenoviruses are nonenveloped icosahedral double stranded DNA viruses with a linear 
genome of ca. 36-kbp. Th ey are known to cause a variety of human diseases including 
respiratory tract infection, conjunctivitis and gastroenteritis. More than 100 diff erent 
adenovirus species have been identifi ed from mammals, birds and reptiles. Th ese viruses 
are classifi ed into six subgroups (from A to F), which are further divided into serotypes 
based on their immunological properties. Serotype 2 and 5 of subgroup C are the most 
extensively studied of the human adenoviruses, and they are found worldwide. Th ey bind 
to a primary receptor on the cell surface, the coxsackie-virus B adenovirus receptor (CAR) 
[227] which in turn activates integrin coreceptors leading to clathrin-mediated endocytosis 
of the adenovirus particle [228]. When the adenovirus genome has reached the nucleus, a 
group of 6 early transcription units (E1A, E1B, E2A, E2B, E3 and E4) are fi rst transcribed. 
Th ese early genes encode proteins involved in DNA replication, host immune system 
suppression (E3) and inhibition of apoptosis of the host cell. Th e E1A- and E1B-encoded 
products regulate cellular genes and transactivate the other early transcription units setting 
in motion the rest of the viral gene expression programme [229]. 
In the recombinant adenoviruses used in these studies, transcription units E1A, E1B as 
well as E3 have been deleted creating a genetic capacity of about 8 kb that can be used for 
DNA insertion. Th e resulting recombinant adenoviruses are helper-independent but can 
proliferate only in transcomplemental cell lines such as 293 or 911 cell lines that express 
the deleted viral genes (reviewed in [230]). 
2. Activin and BMP signalling pathways are involved in the 
induction of inhibin B protein secretion in hGL cells (I) 
Activins and inhibins were fi rst discovered as gonadal proteins that regulate pituitary 
FSH secretion. Th ree types of activin can be produced in the ovary by the granulosa 
cells, each consisting of a dimer of two related subunits, inhibin A and inhibin B. 
Homodimeric activin A  therefore contains two inhibin A subunits, whereas and activin 
B consists of two inhibin B subunits. Th e heterodimeric activin AB is formed from one 
A and one B subunit. Activin produced by the secretory gonadotrophs in the anterior 
pituitary stimulates FSH production in a paracrine manner, and within in the ovary 
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activin promotes granulosa cell proliferation and potentiates FSH actions by increasing 
FSH receptor expression.
Two types of inhibins are also expressed by granulosa cells. Inhibins consist of one 
inhibin -subunit and one inhibin  subunit thus forming either inhibin A ( - A) or 
inhibin B ( - B). Inhibins are also produced by the granulosa cells, and they act as 
endocrine hormones that are released into the circulation to suppress pituitary FSH 
production. Locally, inhibins also act as potent regulators of activin signalling. Inhibins 
compete activin signalling by blocking activin binding to type II activin receptors. -
glycan, an inhibin co-receptor, facilitates inhibin binding to the activin type II receptor.
Inhibin and activin synthesis in the ovary depends on the regulation by the pituitary 
gonadotropins as well as by local paracrine factors. Th e hGL cells from preovulatory 
follicles express inhibin  and inhibin A subunit mRNA, whereas inhibin B subunit can 
not be readily detected [212]. Gonadotropins have been shown to stimulate the expression 
of inhibin  subunit mRNA within 24-48 hours and inhibin A subunit mRNA within 
2 hours as well as the secretion of dimeric inhibin A and B proteins by hGL cells [231, 
232]. Th e expression of the inhibin  subunit decreases during prolonged culture of 
these cells whereas the levels of A subunit remain unchanged [212]. In addition to the 
gonadotropins, TGF- 1 and -2 as well as activin A and BMP-2 can induce the inhibin B 
subunit mRNA expression in cultured hGL cells [219, 232, 233]. 
Th e gonadotropins mediate the induction of inhibin and activin subunits through a 
cAMP-PKA pathway in the ovarian granulosa cells [234] (see Figure 6 in the Review of 
the literature section for a schematic drawing of the signalling pathway), whereas the local 
paracrine factors appear to mediate their eff ect on inhibin production through the Smad 
pathways (Studies I and II). 
To study the role of the TGF-  superfamily receptors and intracellular signalling 
molecules in the induction of inhibin B subunit expression as well as the dimeric 
inhibin B protein production by these ligands, we transduced hGL cells with recombinant 
adenoviruses expressing the individual constitutively active type I receptors ALK1 through 
ALK7 as well as Smad1 and -2. ALK1, -2, -3 and ALK6 are known to activate Smad1, 
-5 and -8 of the BMP-pathway, whereas ALK4, -5 and ALK7 activate the TGF- /activin 
pathway Smads, Smad2 and -3. Th e expression of all the ALK-receptors was detected 
using -HA immunoblotting whereas the Smad proteins were detected using -FLAG 
immunoblotting.
2.1. The expression of constitutively active ALKs activates Smad1 and -2 
pathways
Recombinant adenoviruses were used to express constitutively active (ca)-ALKs to 
enable us to follow the activation of Smad signalling proteins in hGL cells. Th e ca-ALKs 
have distinct point mutations in their kinase domains that enable them to phosphorylate 
their downstream signalling molecules, the Smads, independently of ligand binding [235]. 
Cultured hGL cells were infected with Ad-ca-ALK1-7, and as expected, adenovirally 
expressed constitutively active ALK1, -2, -3 and -6 could specifi cally activate both the 
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endogenous and exogenously expressed Smad1 signalling pathway which was detected 
with a rabbit polyclonal antibody raised against the C-terminal phosphopeptide of Smad1 
( PS1) (I: Fig. 2A and 2B, respectively). 
Ca-ALK4,-5 and -7 activated both the endogenous and exogenous Smad2 protein 
in hGL cells. Th e activation was detected by utilizing a rabbit polyclonal antibody 
raised against the C-terminal phosphopeptide of Smad2 ( PS2), (I: Fig. 2A and 2C, 
respectively). Th e PS1 and PS2 antibodies are specifi c to the phosphorylated forms 
of the Smad proteins and do not recognize the unphosphorylated proteins. However, the 
PS1 antibody is known to cross-react also with the phosphorylated forms of Smad5 and 
-8 as well as Smad3 (Peter ten Dijke, unpublished data). Because of this, additional bands 
that can be seen in Figures 2A and 3A (I) might represent these other Smads. 
In addition, BMP-2 could activate Smad1, with the amount of phosphorylated Smad1 
peaking at 45 minutes and declining thereafter. Correspondingly, activin A was able to 
activate Smad2 protein causing a peak in phosphorylation of Smad2 after 30 minutes 
which started to decline after 60 minutes (I: Fig. 3A and 3B, respectively). 
2.2. The activation of Smad1 and Smad2 pathways promotes inhibin B 
protein secretion in hGL cells
Overexpression of each of the constitutively active ALKs promoted inhibin B protein 
secretion through the activation of Smad1 and Smad2 signalling proteins as measured 
by specifi c inhibin B ELISA. Inhibin B protein concentration was increased in the spent 
hGL media within 48 h after infection with ca-ALK1-7 when compared to controls (I: 
Fig. 4A) while control viruses had no eff ect. Ca-ALK3 and ca-ALK4 viruses signifi cantly 
stimulated the production of dimeric inhibin B within 48 hours depending on the amount 
of virus (I: Fig. 4B(1-2), and 4C(1-2)). Infection with increasing amounts of the Smad1 
and Smad2 viruses caused a corresponding increase in the phospho-Smad1 and phospho-
Smad2 levels, as detected by PS1 and PS2 antibodies (I: Fig. 5C-D, respectively for 
Smad 1 and Smad2) and caused a dose-dependent increase in the secretion of inhibin B 
(I: Fig. 5A and 5B, respectively). 
Th is is in line with earlier results showing that stimulation with either TGF- /activin 
or the BMPs results in the induction of inhibin B secretion in the hGL cells and indicates 
that the Smads participate in the regulation of inhibin production in these cells [219, 233, 
236]. Interestingly, no ligand-induced activation of the Smads was required to induce 
the phosphorylation, but the Smads were spontaneously activated when overexpressed. 
A similar phenomenon has been described before by others for Smad3 [237-239]. It has 
been suggested that the overexpression of Smad3 could overcome the ability of SARA 
(Smad anchor for receptor activation) to bind monomeric unphosphorylated Smad3 and 
prevent the formation of activated trimers in the absence of ligand stimulation [240]. A 
similar mechanism might also regulate the ligand-independent activation of Smad1 and 
Smad2.
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2.3. Kinase defective ALK3 and ALK4 and the inhibitory Smad7 inhibit 
activin and BMP stimulated inhibin B production in hGL cells
Human granulosa luteal cells were infected also with adenoviruses expressing kinase 
defective (kd)-ALK3 and -ALK4 before stimulation with 25 ng/ml BMP-2 or activin A. 
Th e concentration of dimeric inhibin B protein was measured 3 days later in the spent 
media. Th e kinase defective type I receptors act in a dominant negative way and block 
the signalling pathway by inhibiting the activation of the downstream Smad proteins. 
Kd-ALK3 blocked the stimulatory eff ect of BMP-2, whereas kd-ALK4 blocked the 
stimulatory eff ect of activin A on the production of inhibin B dimers (I: Fig. 6A and 6B, 
respectively). 
In addition, the BMP-2 and activin A stimulated inhibin B secretion was signifi cantly 
decreased with the administration of increasing titres of the adenovirus expressing the 
inhibitory Smad7 (I: Fig 7). Th is result is in line with the agreement that Smad7 acts as a 
common inhibitor of both the TGF-  and the BMP ligands [241, 242], (whereas Smad6 
is a specifi c inhibitor of the BMPs [243, 244]).
3. GDF-9 induces the expression of inhibin B subunit mRNAs and 
secretion of dimeric inhibin B protein (II)
Previously, it had been reported that oocyte secreted factors stimulate inhibin A and 
B secretion in rat granulosa cells [245], and that TGF- , activin and some BMPs induce 
inhibin production in hGL cells [219, 233, 236]. We therefore determined whether also 
GDF-9 had any eff ect on the inhibin production in hGL cells. We found that GDF-9 
increased the inhibin B-subunit mRNA steady state levels after 8 h of stimulation (II: 
Fig 3), whereas the inhibin -subunit or inhibin A-subunit transcript levels were not 
distinctly aff ected. However, in cultured rat granulosa cells from small antral follicles, 
GDF-9 has been shown to induce the transcription of the inhibin  as well as the inhibin 
B subunits [246]. Th is discrepancy in the stimulation of inhibin -subunit expression 
might arise from species specifi c diff erences in inhibin/activin production pattern or the 
diff erent stage of follicular development of the granulosa cells.  
Th e concentration of secreted dimeric inhibin B protein was measured from the spent 
media of untreated and GDF-9-stimulated cells using a specifi c inhibin B ELISA. GDF-9 
stimulated the production of inhibin B within 24 h, with the maximal eff ects seen after 72 
h (II: Fig. 3B). GDF-9 induced the inhibin B production in a concentration-dependent 
manner, with maximal stimulations seen at 300 ng/ml GDF-9 (II: Fig. 3C). GDF-9 has 
previously been shown to induce the secretion of both inhibin A and B in the presence or 
absence of FSH in cultured rat granulosa cells from small antral follicles [246]. Similarly, 
denuded bovine oocytes have been shown to produce factors that stimulate inhibin A and 
B protein production, as do TGF-  and activin in rat granulosa cells [245]. 
Since Ad-Smad7 suppressed inhibin B production stimulated by BMP-2 and activin 
A [210], we determined whether overexpression of this inhibitory Smad would also aff ect 
GDF-9-stimulated inhibin B production. Increasing amounts of Ad-Smad7 (m.o.i. values 
of 0.3–30) suppressed GDF-9- induced dimeric inhibin B production in hGL cells dose-
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dependently (II: Fig. 4, A and C), whereas Ad-Smad7 alone did not aff ect basal inhibin B 
levels (II: Fig. 4, B and D). Th ese results suggest that the Smad pathway could be involved 
in the GDF-9-stimulated inhibin B production. 
Small antral follicles are thought to be the principal expression site of the inhibin B 
subunit during folliculogenesis [247-249], which is supported by the increase of circulating 
inhibin B protein levels in the serum at the beginning of the follicular phase during the 
human menstrual cycle [213]. Th erefore, the luteinized human granulosa cells do not 
seem to be the physiological producers of inhibin B, and caution should be kept when 
considering the physiological relevance of these results. However, inhibin B production 
is a convenient parameter to measure when assessing the bioactivity of GDF-9 or other 
superfamily ligands or their signalling pathway in our granulosa cell model. 
4. GDF-9 activates both Smad2 and Smad3 but not Smad1 
pathway in ovarian granulosa cells, HEK 293T as well as the P19 
cell line (II-IV)
4.1. Recombinant GDF-9 induces endogenous PS2 immunoreactive 
proteins in hGL cells
As a member of the TGF-  superfamily, GDF-9 as well, could be predicted to signal 
through the canonical TGF-  superfamily receptor-Smad pathways, and the fi rst evidence 
of this was the report stating that GDF-9 was able to bind the type II receptor BMPRII 
[42]. Because of this it was anticipated that GDF-9 would signal through the BMP-
pathway Smads. 
We established a stable cell line producing the untagged recombinant mouse GDF-
9 and raised a high affi  nity monoclonal antibody against the C-terminal domain of 
human GDF-9 to verify the presence of GDF-9 in the 293T cell-production medium. 
Th e antibody against human GDF-9 was named mAb #37. It detected both the rat and 
mouse recombinant GDF-9 in Western blots analysis of the culture medium of GDF-9-
expressing 293T cells (II: Figure 1A). Th e 293T cell-produced mouse GDF-9 seems to 
be fully processed, whereas the rat GDF-9 consists of the processed mature region as well 
as the unprocessed protein precursor. Both GDF-9 proteins are, however, equally potent 
stimulants when similar amounts of processed mature region proteins are present in the 
293T-conditioned medium. 
We fi rst studied which of the Smad pathways, the TGF- /activin or the BMP 
pathway, was activated by GDF-9 in hGL cells. We followed the activation of the two 
Smad pathways under GDF-9 stimulation by Western blot analyses using the PS1 and 
PS2 antibodies. With GDF-9 stimulation, PS2-reactive bands fi rst appeared within 
30 min of stimulation and peaked within 75 min (II: Fig. 1B, top panel) whereas no 
immunoreactivity was detected in controls. A similar time course for Smad activation has 
been observed by others in diff erent types of cultured cells [250]. 
Induction of the PS2-immunoreactive proteins by GDF-9 was dose-dependent, and 
the strongest eff ect was seen with 150 ng/ml of GDF-9 (II: Fig. 1B, lower panel).  Th e 
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upper panel of Fig. 1C (II) shows that, like TGF- , GDF-9 induced the appearance of 
PS2-immunoreactive protein. PS1-immunoreactive proteins were induced by BMP-2 
but not by TGF-  or GDF-9 (II: lower panel of Fig. 1C). 
Th e PS2- and PS1-immunoreactive bands correspond to the predicted molecular 
masses (~53 kDa) of the phosphorylated Smad2 and Smad1, respectively. It can be therefore 
concluded that GDF-9 uses the same signalling pathway as TGF-  and activin, being able 
to induce the activation of Smad2 pathway instead of the BMP-Smad pathway in the 
human ovarian granulosa cells, despite the fact that it binds the type II BMP receptor [42]. 
Th e ability of GDF-9 to induce Smad2 activation was also tested in another cell model, 
the P19 cell line. GDF-9 treatment stimulated the phosphorylation of Smad2 protein but 
not Smad1, in P19 cells similar to activin (III: Fig 2B). Both these results are in line with 
fi ndings that GDF-9 could activate the Smad2 pathway in cultured rat granulosa cells 
from small antral follicles [246].  
4.2. GDF-9-induced phosphorylation Smad2 in hGL cells is inhibited by
Ad-Smad7
To verify that GDF-9 is actually able to induce phosphorylation of the Smad2 protein, 
we introduced an exogenous Smad2 gene into hGL cells through adenovirus infection. 
Recombinant GDF-9 could stimulate the phosphorylation of both the endogenous and the 
adenovirally produced Smad2 proteins (II: Fig. 2A). At m.o.i. values of 5 or lower, PS2-
reactive bands were rarely seen in unstimulated cells, whereas with Smad2 viruses given 
at m.o.i. values of 10–100, spontaneous activation of Smad2 phosphorylation was clearly 
detected. Th is phenomenon has also been reported by others as R-Smad proteins that are 
overexpressed excessively from expression plasmids have been shown to be spontaneously 
activated in other types of mammalian cells as well [237-239]. Th erefore, Ad-Smad2 m.o.i. 
values of 3–5 were chosen for most experiments to avoid excessive Smad2 expression. 
We next introduced increasing amounts of Ad-Smad6 or Ad-Smad7 (m.o.i. ranging 
from 0.3–30) into hGL cells together with a constant amount of Ad-Smad2 (m.o.i. 5) to see 
whether the inhibitory Smads could block the GDF-9-induced Smad2 phosphorylation. 
Th e GDF-9-induced phosphorylation of both the endogenous and the adenovirally 
expressed Smad2 proteins was gradually reduced close to the control level in cells infected 
with Ad-Smad7 (II: Fig. 2B), whereas Ad-Smad6 was very ineff ective in suppressing Smad2 
phosphorylation (II: Fig. 2C). Th is is in line with earlier fi ndings that Smad7 is a universal 
inhibitor of the TGF-  superfamily ligands and that Smad6 functions specifi cally as a 
BMP-inhibitor [241-244]. 
Th ese results suggest that functionally, GDF-9 should be classifi ed as a TGF- /activin-
like growth factor rather than a BMP-like factor, although phylogenetically GDF-9, as well 
as its close homologue GDF-9B, are closer to the BMP-subgroup than the TGF- /activin-
subgroup [251]. Th e phylogenetic relationship to the BMPs would also be supported by 
the fact that the type II receptor for GDF-9, as well as for GDF-9B, is the type II receptor 
for the BMPs, BMPRII [25, 42]. 
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4.3. Activation of Smad3-specifi c reporter and phosphorylation of Smad3 
in HEK-293T and P19 cells by GDF-9 
Since Smad2 was activated by GDF-9 stimulation in hGL cells, we investigated 
whether GDF-9 could also activate the Smad3 protein. We used plasmid reporter 
constructs that are specifi c for the TGF- /activin Smad3 pathway (CAGA-luciferase) or 
the BMP Smad1/5/8 pathway (BRE-luciferase) in HEK 293T cells. Th e CAGA-luciferase 
reporter construct consists of twelve tandem repeats of the Smad binding element located 
in the plasminogen activator inhibitor (PAI) promoter, and is specifi cally activated by 
phosphorylated form of Smad3, downstream of ALK4, -5 and -7 receptors [205]. It is not 
activated by the phosphorylated Smad2. 
Th e BRE-luciferase reporter construct contains a BMP-specifi c response-element from 
the Id1 (inhibitor of diff erentiation 1) promoter and is specifi cally activated by Smad1, 
-5 and -8 [206]. We found that the HEK-293T cell line was very responsive to GDF-9, 
and the responsiveness was measured by the induction of the CAGA-luciferase reporter 
activity (IV: Fig. 1A). In the same cell line, the BMP-responsive reporter construct, BRE-
luciferase, was only activated by BMP-2 and not by GDF-9 (IV: Fig. 1B). GDF-9 activated 
the CAGA promoter in 293T cells dose-dependently (IV: Fig. 1C). 
Th ese results were repeated in another cell line, the mouse embryonic carcinoma-
derived P19 cells. As shown in Fig. 1A (III), treatment of P19 cells with GDF-9 induced 
the activation of the CAGA luciferase reporter like TGF-  and activin. Although BMP-2 
was ineff ective on the CAGA promoter (III: Fig. 1A), treatment with BMP-2, stimulated 
the reporters driven by the BRE or the GCCG-promoter whereas GDF-9, TGF- , or 
activin had no eff ect (III: Fig. 1, B and C, respectively). Furthermore, GDF-9 stimulation 
of the CAGA promoter was dose-dependent (III: Fig. 1D). Th ese fi ndings suggest that 
also P19 cells express the receptors and downstream eff ectors that are required for GDF-9 
signalling.
Because GDF-9 was able to activate the Smad3-dependent CAGA promoter, we 
also examined whether it could cause the phosphorylation of Smad3 protein in GDF-9-
treated 293T and P19 cells. As expected, GDF-9 increased the level of phosphorylated 
recombinant Smad3 (IV: Fig. 1D) in 293T cells. GDF-9 also increased the level of 
phosphorylated Smad3 in the P19 cells as shown in Fig. 2 A (III). 
4.4. Activation of a Smad3-specifi c reporter in hGL and rat granulosa 
cells by GDF-9, TGF-  and activin and phosphorylation of Smad3 in rat 
granulosa cells
Because we had observed the activation of Smad3 by GDF-9 in human 293T cells and 
P19 cells (IV: Fig. 1D and III: Fig. 2), we wanted to determine whether GDF-9 activated 
Smad3 in primary cultures of hGL cells (II: Fig. 1B and C). We introduced an adenovirus 
expressing a (CAGA)9-luciferase into hGL cells, and stimulated the cells with diff erent 
ligands. GDF-9, TGF- , and activin all activated the (CAGA)9-luciferase reporter in hGL 
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cells dose-dependently (IV: Fig. 2) whereas BMP-2 did not (IV: Fig. 2C) demonstrating 
the specifi city of the assay for Smad3-activating ligands. GDF-9 treatment also increased 
the CAGA promoter activity dose-dependently in granulosa cells obtained from early 
antral follicles of immature rats transfected with the CAGA-promoter, as did activin and 
TGF-  (III: Fig. 7A and B ). 
Our earlier data had demonstrated the ability of GDF-9 to stimulate Smad2 
phosphorylation in rat granulosa cells [246] and because studies using P19 cells 
demonstrated the ability of GDF-9 to stimulate Smad3 phosphorylation, we tested 
whether treatment with GDF-9 could induce the phosphorylation of Smad3 proteins 
also in rat granulosa cells. As shown in Fig. 7C (III), treatment with GDF-9, like activin, 
increased the level of phosphorylated Smad3 protein. Th ese data suggested that the 
GDF-9 stimulation of the CAGA promoter is correlated with its stimulation of Smad3 
phosphorylation in granulosa cells. 
4.5. GDF-9 stimulation of the CAGA promoter is blocked by the inhibitory 
Smad7 but not by Smad6 in both  rat granulosa cells and the P19 cells 
Because the transcriptional activities of all R-Smad proteins (Smad1, -2, -3, -5, and 
-8) are blocked by the inhibitory Smad7, whereas those of Smad1, -5, and -8 are blocked 
by the inhibitory Smad6, we tested the inhibitory activities of the two inhibitory Smad 
proteins in P19 cells and rat granulosa cells treated with GDF-9. Figure 3A (III) shows 
that a cotransfection with Smad7, but not Smad6, led to a dose-dependent suppression 
of the GDF-9 stimulation of the CAGA promoter together with a minor inhibition 
of the basal promoter activity. Consistent with the role of Smad1, 5, and 8 in BMP-2 
signalling, treatment with either Smad6 or Smad7 blocked the BMP2 stimulation of the 
BRE promoter in the same cells (III: Fig. 3B). 
Th ese results suggest that GDF-9 signalling does not involve the BMP-responsive 
pathway mediated by Smad1, 5, and 8 and likely involves Smad2 and Smad3 activated 
by ALK4, 5, or 7. We further tested the eff ect of inhibitory Smad proteins on GDF-9 
signalling in the rat granulosa cells. As shown in Fig. 8 (III), transfection of these cells with 
the inhibitory Smad7 suppressed GDF-9 stimulation of the CAGA promoter, consistent 
with our fi ndings derived from P19 cells. In contrast, only minimal suppression of GDF-
9 eff ects was observed when cells were transfected with the highest dose (150 ng) of 
Smad6. 
Both Smad2 and Smad3 are expressed in the ovary at the stages of follicular 
development when GDF-9 is expressed [252]. Both Smads are present in rat preantral 
follicles but disappear from large antral follicles. Smad2 expression returns in luteal cells, 
whereas Smad3 remains absent. Smad2 has been shown to be more responsive to activin 
and Smad3 to TGF-  signalling in rat granulosa cells [252]. Stage-specifi c expression and 
diff ering ligand sensitivity of signalling molecules may work together to allow diff erent 
eff ects of TGF-  family ligands using the same signalling pathways over the course of 
follicular development.
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5. GDF-9 signalling is mediated by the type I receptor ALK5  (III 
and IV) 
Th e type II receptor for GDF-9 was discovered in 2002 by Vitt et al. Th e BMP type 
II receptor  (BMPRII) soluble ectodomain was shown to be most eff ective in blocking the 
GDF-9-induced granulosa cell proliferation and suppression of FSH-induced progesterone 
production [42]. In addition, GDF-9 showed a direct interaction with BMPRII ectodomain 
in a co-precipitation study, whereas ActRIIA ectodomain showed only minimal interaction 
and could only partially block granulosa cell proliferation [42]. Th e BMP type I receptors 
ALK3 and -6 also partially inhibited the GDF-9-induced granulosa cell proliferation, 
whereas ALK2 had no eff ect. In binding studies, none of these ALKs showed interaction 
with GDF-9. Th ese results with the BMP ALKs are curious, since sequence alignment of 
GDF-9 had revealed that it is most closely related to the BMPs, and therefore might have 
been thought to signal via the BMP pathway receptors and Smads. 
A close homologue of GDF-9, GDF-9B, has also been shown to bind BMPRII but has 
high affi  nity to ALK-6 [25]. GDF-9B induces the activation of Smad1/5/8 pathway but 
curiously is also able to activete the Smad2/3 pathway in COV434 cells, although weakly 
[25]. Th us, knowing that GDF-9 induces a TGF- /activin-like response in stimulating 
the activation of Smad2/3 pathway, the group of type I receptors capable of mediating the 
GDF-9 signal would be ALK4, -5 or -7. Th erefore, the following studies were conducted 
to elucidate the type I receptor for GDF-9.
5.1. Adenoviral overexpression of wild-type ALK5 and ALK4 amplifi es 
the CAGA-luciferase response of hGL cells to GDF-9/TGF-  and activin, 
respectively
We studied the eff ect of adenoviral-mediated overexpression of either ALK5 or ALK4 
in hGL cells on the GDF-9, TGF- , or activin response, and measured their eff ects in 
the Smad3-responsive CAGA-luciferase reporter assay. Overexpression of ALK5 enhanced 
the response of hGL cells to GDF-9 and TGF-  stimulation dose-dependently but not to 
activin (IV: Fig. 3A). In contrast, the overexpression of ALK4 did not aff ect the GDF-9 
response of the transduced hGL cells, but caused a strong dose-dependent response to 
activin in these cells (IV: Fig. 3B). 
5.2. Effect of overexpression of type I receptors Alk5 and Alk4 in hGL cells 
on GDF-9-induced inhibin B production 
We have shown that GDF-9 stimulates the production of inhibin B by hGL cells and 
rat granulosa cells ([246] and study II). Th erefore we examined the eff ect of overexpression 
of either ALK5 or ALK4 in hGL cells on the GDF-9 response, and measured the level of 
inhibin B in the culture medium from the adenovirally transduced cells. Overexpression 
of ALK5 caused a strong potentiation in the response of hGL cells to GDF-9 (IV: Fig. 
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4A), whereas the TGF- -stimulated inhibin B response was less aff ected by the ALK5 
expression level. Th e eff ect of overexpression of ALK4 on the GDF-9 response was minimal 
(IV: Fig. 4B). Overexpression of ALK4 alone was enough to cause an increase in the level 
of inhibin B produced by hGL cells, and the eff ect of GDF-9 treatment on these cultures 
was only additive in terms of inhibin B production.
5.3. Overexpression of ALK5 and Smad3 confers GDF-9 responsiveness in 
the nonresponsive COS7 cells 
In preliminary tests, it was found that GDF-9 treatment could not activate the CAGA 
and BRE promoters in COS7 cells (III: Fig. 4A). However, these cells were responsive 
to TGF-  and activin based on the stimulation of the CAGA promoter (III: Fig. 4A), 
but also the BRE promoter-reporter was activated by BMP2 and BMP7 (III: Fig. 4B), 
suggesting that the COS7 cells express BMPRII to mediate BMP actions as well as ALK4, 
ALK5, and Smad3 to mediate the actions of TGF-  and activin. We hypothesized that the 
endogenous levels of one or more of the type I receptors, the type II BMPRII receptor, 
and/or Smad2 or Smad3 were too low in COS7 cells to allow effi  cient GDF-9 signalling. 
We therefore performed overexpression tests in COS7 cells in an attempt to gain GDF-9 
responsiveness.
Transfection of these cells with increasing amounts of the ALK5 expression plasmid led 
to a dose-dependent stimulation of the CAGA promoter activity by GDF-9 (III: Fig. 5A). 
In these cells, transfection with the ALK5 plasmid also increased TGF- , whereas activin 
signalling was not aff ected. However, transfection of increasing amounts of the ALK4 
plasmid alone led to a dose-dependent increase in luciferase activity (III: Fig. 5B, left 
panel). In these ALK4-transfected cells, treatment with GDF-9 and TGF-) was ineff ective 
in further stimulating the CAGA promoter, in contrast to activin treatment. In addition, 
overexpression of ALK7 did not confer hormonal responsiveness to GDF-9, activin, or 
TGF-  (III:  Fig. 5C). In addition, overexpression of ALK1, 2, 3, or 6 did not confer 
GDF-9 activation of the CAGA promoter. 
Because the CAGA promoter is responsive to Smad3, but not Smad2, activation 
(Table 1, III), we further tested whether transfection with Smad3, alone or together 
with ALK5, could render the COS7 cells responsive to GDF-9. As shown in Fig. 6 (III), 
cells overexpressing Smad3 did not show increased GDF-9 responsiveness. However, 
cotransfection of the Smad3 plasmid with a submaximal level (10 ng) of the ALK5 
plasmid further augmented the GDF-9 stimulation of the CAGA promoter. Th ese data 




5.4. Inhibitory effects of ALK5 siRNA on GDF-9 signalling in granulosa cells
We further tested whether granulosa cells, like COS7 cells, require ALK5 for GDF-
9 signalling. Control and ALK5 siRNAs were transfected into cultured granulosa cells 
before testing the ability of GDF-9 to activate the CAGA promoter. Small interfering 
RNAs act post-transcriptionally and degrade the targetted mRNAs in a sequence-specifi c 
manner causing the silencing of the intended gene [253]. As shown in Fig. 9A (III), 
transfection with increasing amounts of ALK5 siRNA led to dose-dependent decreases 
in CAGA promoter activity stimulated by GDF-9, whereas control siRNA had no eff ect. 
Treatment with ALK5 siRNA also suppressed CAGA promoter activity stimulated by 
TGF-  (III: Fig. 9B), while no inhibition of CAGA promoter activity by activin was 
observed (III: Fig. 9C). Th ese fi ndings demonstrated the important role of ALK5 in GDF-
9 actions in granulosa cells.
 
6. GDF-9 signalling pathway
Th e receptor complex utilized by the oocyte-derived growth diff erentiation factor GDF-
9 thus consists of the type II BMP receptor BMPRII and the activin-receptor like kinase 
ALK5. Upon GDF-9 binding and the formation of the active receptor-ligand complex at 
the plasma membrane, the intracellular eff ectors the Smads 2 and 3 are activated. Th ese 
Figure 7. A schematic drawing of the Smad signalling pathway utilized by GDF-9.
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proteins translocate into the nucleus in complex with the common-partner Smad4 to 
modulate target gene transcription (Figure 7). 
Th e receptor combination utilized by GDF-9 is uncommon in that this case is the 
fi rst time that BMPRII has been reported to associate with ALK5. Th is kind of cross-
talk between the established TGF- /activin and BMP pathway receptors is not unique, 
however, since T RII can interact also with ALK1 in addition to ALK5 [254]. ALK5 had 
previously been shown to bind only TGF-  [51] and myostatin (GDF-8) [255]. 
Based on these studies, we can show that also GDF-9 can stimulate the activation of 
both the Smad2 and Smad3 proteins through ALK5. It is not known yet however, to what 
extent each of these Smads contributes to the modulation of target genes. In the case of 
TGF- , it is known that the Smad2 and -3 have diff erent downstram eff ects [256]. In 
addition, Smad2 knockout mice die early during embryogenesis [257, 258] while mice 
lacking functional Smad3 are viable. Th e diff erent Smad3 knockout mice can display 
either impaired folliculogenesis due to diminished pool of follicles reaching the antral 
stage [259] or only smaller litter sizes compared to wild type mice depending on the 
location of disruption in the gene (deletions in exon 8 and exon 2, respectively) [260]. 
Th e delayed follicular maturation in Smad3 defi cient mice with deletion in exon 8 could 
be caused by impaired GDF-9 signalling.
Our results concerning the signalling components and pathways have been obtained 
in in vitro culture conditions both in primary somatic ovarian cells and various stable 
cell lines. Th ese cell models can not, however, mimic the physiological conditions within 
the ovary, and therefore these models can only give a rather static view of the signalling 
phenomenon. For example, the proper spatial and temporal dimensions of the signalling 
compoments and ligands are lacking in these models. Th erefore, what we see is only an 
over-simplifi ed picture. Gilchrist and his research group have utilized a diff erent approach 
for studying the oocyte-derived growth factors and their signalling mechanisms. His 
group has used intact denuded oocytes (DO) from cumulus oocyte complexes (COC) 
and oocytectomized (OOX) cumulus cell complexes and under these conditions the 
physiological environment of the follicle may be better imitated. 
In a recent article by Gilchrist et al. it was shown that the oocyte secreted factor(s) 
(OSF), most likely including both GDF-9 and GDF-9B, principally use the Smad2/3 
pathway for stimulating granulosa cell growth [261]. Surprisingly, the BMP Smad 
pathway was not found to be activated despite the fact that the oocyte expressed growth 
diff erentiation factor GDF-9B is a granulosa cell mitogen [176] and is known to signal 
through the Smad1/5/8-pathway [261]. Also, the OSF seem to signal predominantly 
through the BMPRII receptor, since the soluble ectodomain of the BMPRII could block 
the oocyte-induced granulosa cell thymidine incorporation completely [261]. However, 
the oocytes used in Gilchrist’s study [261] were derived from preovulatory antral follicles 
of immature mice primed with equine chorionic gonadotropin which may not express 
functional GDF-9B as is suggested by Yoshino et al. in their recent article. Yoshino et al. 
found that the functional mature form of GDF-9B is markedly expressed only just before 
ovulation in mouse oocytes, which could explain the absence of the BMP-Smad activation 
[181]. 
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Yoshino also showed that recombinant GDF-9B is able to induce cumulus expansion 
in mouse cumulus-oocyte complexes [181] in the absence of FSH. GDF-9B stimulated 
the expression of EGF-like growth factors betacellulin, epiregulin and amphiregulin in 
cumulus cells as well as a series of molecules downstream of EGF-like growth factor 
signaling, including cyclooxygenase 2 (COX2), hyaluronan synthase 2 (HAS2), tumor 
necrosis factor-stimulated gene 6 (TNFIP6), and pentraxin 3 (PTX3), all of which are 
necessary for normal cumulus expansion. 
Cumulus expansion has now been shown to be induced by both of the oocyte-expressed 
growth factors, GDF-9 [138, 170] and GDF-9B [181], in addition to FSH or epidermal 
growth factor (EGF) [262, 263]. Th e combined stimulation by these aforementioned 
factors results in the activation of MAPK3/1 (ERK1/2) and MAPK14 (p38) proteins 
[264, 265] to enable the up-regulation of downstream targets HAS2, COX2 (Ptgs2), 
TNFIP6 and PTX3 required for expansion [266]. Th us, the oocyte-enabled activation of 
the MAPK pathway in cumulus cells is required for their expansion [264], and inhibition 
of the MAPK activation prevents the rise in HAS2 and COX2 expression [267]. Oocytes 
from preantral follicles do not seem to secrete active cumulus expansion enabling factor, 
whereas only fully-grown oocytes are competent to enable expansion [266]. 
Dragovic et al. reported recently that the oocyte secreted CEEF is likely composed 
of TGF-  superfamily ligands that signal through the Smad2/3 pathway to enable the 
initiation of cumulus expansion [129] and that the BMP-Smad pathway does not contribute 
to the signalling mechanism involved in initiating cumulus expansion either, although 
GDF-9B is present. Could the CEEF secreted by the oocytes then be a heterodimer of 
GDF-9 and GDF-9B? Th ese ligands have been shown to be able to form a heterodimeric 
protein in vitro [201]. However, the signalling mechanisms of the heterodimer have not 
been reported as of yet although it could be predicted that the receptor complex would 
consist of BMPRII, ALK5 and ALK6, and that both Smad2/3 and Smad1/5/8 pathways 
are activated. In this case, based on the evidence by Dragovic et al. it would mean that 
also the heterodimer signals predominantly through the TGF- /activin pathway. Defects 
in heterodimer formation could thus be the reason for defects in cumulus expansion in 
GDF-9/-9B double knockout and ALK6 knockout mice. Double mutant mice completely 
lacking GDF-9B and carrying only one functional allele of GDF-9 have been shown to 
exhibit defects in cumulus expansion [268]. In addition, ALK6 knockout female mice 
are infertile, primarily due to impaired cumulus expansion [269]. However, the oocyte-
induced cumulus expansion can only partially be blocked by the BMPRII ectodomain 
[170], suggesting that other signalling pathways may also be involved in the induction of 
cumulus expansion by the oocyte. 
In addition to the canonical TGF-  signalling pathway, GDF-9 has been reported 
to be able to activate other signalling pathways as well. Orisaka et al., recently reported 
that GDF-9 is antiapoptotic during preantral and early antral stage and that this eff ect 
is mediated via phosphatidylinositol 3-kinase/akt pathway [270]. In addition, Su et al. 
showed that MAPK activation is required for GDF-9 to enhance cumulus expansion, 
suggesting that MEK-MAPK pathway interacts with GDF-9 signal transduction cascade 
[264].
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SUMMARY AND CONCLUDING REMARKS
Th e main aim of this thesis project was to discover the signalling pathway used by the 
oocyte-derived growth factor GDF-9. We took advantage of recombinant adenoviruses 
expressing the diff erent components of the TGF-  superfamily signalling pathway to be 
able to manipulate the signalling cascade at diff erent levels in primary cultures of human 
granulosa-luteal cells. We found that overexpression of the constitutively active forms of 
the type I receptors, ALKs 1 through 7, caused the specifi c activation of either the Smad1 
or Smad2 pathway. Th e activation of these Smads stimulated the expression of dimeric 
inhibin B protein in human granulosa-luteal cells. 
One of the fi ndings of this thesis was that both TGF- /activin- and BMP-activated 
Smad pathways contribute to inhibin B secretion in hGL cells. It was also found that 
GDF-9 stimulated inhibin B production as has previously been shown for TGF-  and 
BMPs. Small antral follicles are thought to be the principal expression site of the inhibin 
B subunit during folliculogenesis [247-249], which is supported by the increase of 
circulating inhibin B protein levels in the serum at the beginning of the follicular phase 
during the human menstrual cycle [213]. Th erefore, the luteinized human granulosa cells 
may not be the physiological producers of inhibin B, and caution should be kept when 
considering the physiological relevance of these results. However, inhibin B production 
was a convenient parameter to measure when assessing the bioactivity of GDF-9 or other 
superfamily ligands or their signalling pathway in the granulosa luteal cell model. 
In the human granulosa-luteal cells, treatment with recombinant GDF-9 induced the 
specifi c activation of the Smad2 pathway and stimulated the expression of inhibin B 
subunit mRNA as well as inhibin B protein. We demonstrated that the Smad3-responsive 
CAGA-luciferase reporter construct was activated by GDF-9, providing evidence that also 
Smad3 is involved in GDF-9 signalling. Adenovirus-mediated overexpression of wild-type 
receptors of the TGF-  superfamily was used to amplify the cellular response to diff erent 
ligands, and consequently, GDF-9 response in human granulosa luteal cells was markedly 
enhanced when ALK5 was overexpressed. ALK5 overexpression also potentiated the GDF-
9 induced inhibin B secretion by these cells. Similarly, in P19 cells GDF-9 activated both 
Smad2 and -3 proteins, and overexpression of ALK5 in COS7 cells made them responsive 
to GDF-9. In rat granulosa cells small interfering RNAs for ALK5 could block the GDF-
9 stimulated activation of the CAGA-luciferase reporter construct. Overexpression of the 
inhibitory Smad7 also resulted in dose-dependent suppression of GDF-9 eff ects. 
In summary, we found that like other TGF-  family ligands, also GDF-9 signalling is 
mediated by the canonical type I and type II receptors, namely the ALK5 and BMPRII, 
respectively, and their intracellular eff ectors, the Smad2 and -3. We found that despite 
binding to the BMP type II receptor, the downstream eff ects of GDF-9 are mediated 
by the type I receptor, ALK5 on the cell membrane level and within the cell by the 
transcription factors Smad2 and Smad3. Both TGF- /activin- and BMP-pathway Smads 
may be involved in controlling the regulation of inhibin B secretion. Th erefore, in addition 
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to the endocrine control of inhibin production by gonadotropins, also paracrine factors 
produced locally within the ovary, like the oocyte-derived growth factors, may contribute 
to controlling inhibin secretion. 
Future directions
Although our knowledge of the oocyte growth factors GDF-9 and GDF-9B has 
increased with accelerating speed, there are still a lot of open questions about the biological 
roles of these proteins within the ovary. Th e future challenges in studying the diff erent 
roles of GDF-9, as well as its close homologue GDF-9B during folliculogenesis include 
fi nding out what their physiological eff ects are at diff erent stages of folliculogenesis in 
vivo, and whether they actually function as homodimers or a heterodimer or both, and 
whether the formation of the putative heterodimer is temporarily regulated. Important 
future challenges are also to study the signalling mechanisms of GDF-9 and GDF-9B in 
in vivo context, as well as to conduct binding studies with iodinated proteins to reveal the 
whole receptor complex used by GDF-9,GDF-9B or the putative heterodimer (including 
possible accessory receptors). Th is of course requires the ability to produce very pure 
protein preparations. Th e signifi cance of the alternative signalling pathways for GDF-9 
and GDF-9B in folliculogenesis also remains to be further studied. It would be interesting 
to fi nd out what the interaction patterns of these proteins are in diff erent species. In 
addition, one important line of study is the eff ect of the pro-regions on the bioactivity of 
both of these ligands. It would also be of interest to study whether GDF-9 binding small 
molecules could be used to control female fertility.
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